var docs;if (!docs) docs =[]; docs["34"]={"3401":"<p><b>Title</b> Lithium / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of neurotoxicity (e.g., ataxia, dysarthria, tremor, nausea) and changes in lithium serum concentrations if verapamil or diltiazem is initiated/dose changed. Signs and symptoms of toxicity may appear without an associated increase in lithium concentrations.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem*, Verapamil*<br><b>Exception</b> Bepridil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Signs and symptoms of lithium toxicity (ataxia, muscle weakness, nausea, vomiting, tinnitus) developed in a patient within 9 days of initiating verapamil (240 mg/day).<sup>1</sup> The patient's lithium dose was 900 mg daily (as carbonate). The intoxication resolved within 2 days of discontinuing the verapamil. Her serum lithium concentration remained unchanged during the entire ordeal. Several other similar cases have been reported involving both verapamil<sup>2,3,4,5</sup> and diltiazem.<sup>6</sup> In contrast to many other cases, verapamil (240mg daily) was associated with a significant increase in lithium concentrations in one report, though lisinopril and aspirin, both of which are also known to interact with lithium, were started concurrently with verapamil and likely account for at least some of the observed increase in lithium concentrations.<sup>2</sup> A dissimilar report describes a reduction in serum lithium concentrations in two patients following the initiation of verapamil.<sup>7</sup> The mechanisms of these varied effects are not fully understood.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Price WA and Giannini AJ, “Neurotoxicity Caused by Lithium-Verapamil Synergism,” <i> J Clin Pharmacol</i>, 1986, 26:717-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3793965\">[PubMed 3793965]</a></p>\n<p>2. Chandragiri SS, Pasol E, Gallagher RM, “Lithium, ACE Inhibitors, NSAIDs, and Verapamil. A Possible Fatal Combination,” <i>Psychosomatics</i>, 1998, 39(3):281-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9664775\">[PubMed 9664775]</a></p>\n<p>3. Price WA and Shalley JE, “Lithium-Verapamil Toxicity in the Elderly,” <i>J Am Geriatr Soc</i>, 1987, 35:177-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3100605\">[PubMed 3100605]</a></p>\n<p>4. Wright BA, Jarrett DB, “Lithium and Calcium Channel Blockers: Possible Neurotoxicity,” <i>Biol Psychiatry</i>, 1991, 30(6):635-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1932412\">[PubMed 1932412]</a></p>\n<p>5. Dubovsky SL, Franks RD, Allen S, “Verapamil: A New Antimanic Drug with Potential Interactions with Lithium,” <i>J Clin Psychiatry</i>, 1987, 48(9):371-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3114243\">[PubMed 3114243]</a></p>\n<p>6. Binder EF, Cayabyab L, Ritchie DJ, et al, “Diltiazem-Induced Psychosis and a Possible Diltiazem-Lithium Interaction,” <i>Arch Intern Med</i>, 1991, 151:373-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1899553\">[PubMed 1899553]</a></p>\n<p>7. Weinrauch LA, Belok S, and D’Elia JA, “Decreased Serum Lithium During Verapamil Therapy,” <i>Am Heart J</i>, 1984, 108:1378-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6541864\">[PubMed 6541864]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3402":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Antipsychotic Agents (First Generation [Typical])</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combination of typical antipsychotics and a dopamine agonist should generally be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to inhibit anti-Parkinson activity. Otherwise, alternative therapies should be considered. If typical antipsychotics and dopamine agonists are used concurrently, monitor for reduced effects of both therapies.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine*, Levodopa*, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n <p><b>Antipsychotic Agents (First Generation [Typical]) Interacting Members</b> Benperidol, Bromperidol, ChlorproMAZINE*, Droperidol, Flupentixol, FluPHENAZine, Haloperidol*, Loxapine, Methotrimeprazine, Molindone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Thiothixene, Trifluoperazine, Zuclopenthixol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe reduced therapeutic response of Parkinsonism to levodopa in patients concurrently treated with phenothiazines.<sup>1,2</sup> A single case report describes increases in serum prolactin concentrations in a bromocriptine-treated patient with a prolactin-secreting pituitary tumor each time thioridazine was added to his regimen for the treatment of a psychiatric disorder.<sup>3</sup> The serum prolactin concentrations increased as much as fivefold during concomitant therapy, and returned to normal following discontinuation of the thioridazine. The patient was rechallenged twice with similar results. <br><br>Studies have demonstrated an ability of typical psychotics to inhibit levodopa effects including anti-Parkinson's effects,<sup>4</sup> induced involuntary movements,<sup>4</sup> and growth hormone stimulation.<sup>5</sup> Further, two studies have shown reduced induction of prolactin release by atypical antipsychotics with concomitant levodopa.<sup>6,7</sup><br><br>These interactions are likely the consequence of opposing dopaminergic mechanisms of action of the anti-Parkinson's dopamine agonists and dopamine antagonist antipsychotics. If possible, typical antipsychotics should be avoided in combination with dopamine agonists.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Duvoisin RC, “Diphenidol for Levodopa-Induced Nausea and Vomiting,” <i>JAMA</i>, 1972, 221:1408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5068561\">[PubMed 5068561]</a></p>\n<p>2. Campbell JB, “Long-Term Treatment of Parkinson’s Disease With Levodopa,” <i>Neurology</i>, 1970, 20(December Suppl):18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4991656\">[PubMed 4991656]</a></p>\n<p>3. Robbins RJ, Kern PA, and Thompson TL II, “Interactions Between Thioridazine and Bromocriptine in a Patient With a Prolactin-Secreting Pituitary Adenoma,” <i>Am J Med</i>, 1984, 76:921-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6720732\">[PubMed 6720732]</a></p>\n<p>4. Tarsy D, Parkes JD and Marsden CD, “Metoclopramide and Pimozide in Parkinson's Disease and Levodopa-Induced Dyskinesias,” <i>J Neurol Neurosurg Psychiatry</i>, 1975, 38(4):331-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1095689\">[PubMed 1095689]</a></p>\n<p>5. Mims RB, Scott CL, Modebe O, et al, “Inhibition of L-dopa-Induced Growth Hormone Stimulation by Pyridoxine and Chlorpromazine,” <i>J Clin Endocrinol Metab</i>, 1975, 40(2):256-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1117978\">[PubMed 1117978]</a></p>\n<p>6. Delitala G, “Stimulating Action of Sulpiride and Pimozide on Prolactin Release. Effect of Bromocriptine, L-Dopa, and metergoline Administration,” <i>Acta Endocrinol (Copenh)</i>, 1977, 86(2):251-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=578618\">[PubMed 578618]</a></p>\n<p>7. Vaidya RA, Sheth AR, Aloorkar SD, et al, “The Inhibitory Effect of the Cowhage Plant-Mucuna Pruriens-and L-Dopa on Chlorpromazine-Induced Hyperprolactinemia,” <i>Neurol India</i>, 1978, 26(4)177-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=753997\">[PubMed 753997]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3403":"<p><b>Title</b> Isoniazid / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced effects of isoniazid in patients receiving concomitant systemic corticosteroids.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Serum isoniazid concentrations (based on 10 mg/kg/day) were decreased 23% to 38% in 26 patients 8.5 hours after the administration of a single dose of prednisolone (20 mg).<sup>1</sup> The reasons for these changes are not clear. No evidence of negative clinical effects was provided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sarma GR, Kailasam S, Nair NG, et al, “Effect of Prednisolone and Rifampin on Isoniazid Metabolism in Slow and Rapid Inactivators of Isoniazid,” <i>Antimicrob Agents Chemother</i>, 1980, 18:661-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7447424\">[PubMed 7447424]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3405":"<p><b>Title</b> Cefpodoxime / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Cefpodoxime. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of oral cefpodoxime if an antacid is initiated/dose increased. Consider administering antacids and cefpodoxime at least 2 hours apart.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The AUC of cefpodoxime proxetil was reduced by approximately 40% when coadministered with aluminum/magnesium hydroxide.<sup>1,2</sup> Similarly, administration with the H2-receptor antagonist famotidine was also associated with an average 40% decrease in cefpodoxime AUC in a study of 10 healthy volunteers.<sup>1</sup><br><br>An interaction with acid-reducing therapies has also been noted with the cephalosporin antibiotic cefuroxime. The AUC of cefuroxime axetil was reduced by more than 60% when coadministered with a combination of ranitidine and sodium bicarbonate.<sup>3</sup> However, the cephalosporins cefixime, cefprozil, cephalexin, and ceftibutin do not appear to be significantly affected by antacid administration.<sup>4,5,6,7</sup><br><br>The mechanism of the this cefpodoxime interaction is uncertain, but given the consistent findings with both antacids and H2-antagonists, it appears to be pH-related (vs. chelation, etc.).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Saathoff N, Lode H, Neider K, et al, “Pharmacokinetics of Cefpodoxime Proxetil and Interactions With an Antacid and an H2-Receptor Antagonist,” <i>Antimicrob Agents Chemother</i>, 1992, 36:796-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1354432\">[PubMed 1354432]</a></p>\n<p>2. Hughes GS, Heald DS, Barker KB, et al, “The Effects of Gastric pH and Food on the Pharmacokinetics of a New Oral Cephalosporin, Cefpodoxime Proxetil,” <i>Clin Pharmacol Ther</i>, 1989, 46:674-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2557183\">[PubMed 2557183]</a></p>\n<p>3. Sommers De K, Van Wyk M, Moncrieff J, et al, “Influence of Food and Reduced Gastric Acidity on the Bioavailability of Bacampicillin and Cefuroxime Axetil,” <i>Br J Clin Pharmacol</i>, 1984, 18:535-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6091711\">[PubMed 6091711]</a></p>\n<p>4. Healey DP, Sahai JV, Sterling LP, et al, “Influence of an Antacid Containing Aluminum and Magnesium on the Pharmacokinetics of Cefixime,” <i>Antimicrob Agents Chemother</i>, 1989, 33:1994-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2610509\">[PubMed 2610509]</a></p>\n<p>5. Shyu WC, Wilber RB, Pittman KA, et al, “Effect of Antacid on the Bioavailability of Cefprozil,” <i>Antimicrob Agents Chemother</i>, 1992, 36:962-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1510420\">[PubMed 1510420]</a></p>\n<p>6. Deppermann KM, Lode H, Hoffken G, et al, “Influence of Ranitidine, Pirenzepine, and Aluminum Magnesium Hydroxide on the Bioavailability of Various Antibiotics, Including Amoxicillin, Cephalexin, Doxycycline, and Amoxicillin-Clavanulanic Acid,” <i>Antimicrob Agents Chemother</i>, 1989, 33(11):1901-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2610502\">[PubMed 2610502]</a></p>\n<p>7. Radwanski E, Nomeir A, Cutler D, et al, “Pharmacokinetics of Ceftibuten Administered With and Without Mylanta II or Ranitidine,” <i>Pharm Res</i>, 1993, 10(10 Suppl):S-310.]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3406":"<p><b>Title</b> Cefuroxime / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction only applies to orally administered cefuroxime axetil. This interaction does not apply when cefuroxime is administered via the intravenous or intramuscular routes.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Cefuroxime. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 6 healthy volunteers, the AUC of cefuroxime (given as a single dose of 1,000 mg cefuroxime axetil) was reduced by more than 60% when coadministered with a combination of ranitidine and sodium bicarbonate.<sup>1</sup><br><br>In contrast, in a pharmacokinetic study of 7 dialysis patients, aluminum hydroxide (1,000 mg single dose) administered prior to cefuroxime axetil (1,000 mg single dose) had no effect on the maximum serum concentration or AUC of cefuroxime.<sup>2</sup><br><br>The cefuroxime axetil prescribing information states that because drugs that reduce gastric acidity may reduce the bioavailability of cefuroxime, cefuroxime axetil should be administered at least 1 hour before or 2 hours after the administration of short-acting antacids.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. <i>Br J Clin Pharmacol</i>. 1984;18(4):535-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6091711\">[PubMed 6091711]</a></p>\n<p>2. Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. <i>Adv Perit Dial</i>. 1994;10:179-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7999822\">[PubMed 7999822]</a></p>\n<p>3. Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3407":"<p><b>Title</b> Vitamin K Antagonists / Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may enhance the anticoagulant effect of Vitamin K Antagonists. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Increase frequency of INR monitoring and monitoring for signs/symptoms of bleeding in patients who are receiving an oral vitamin K antagonist anticoagulant and a COX-2 inhibitor. Particular caution should be used during the first several days and weeks of concurrent use.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) Interacting Members</b> Celecoxib*, Etoricoxib, Morniflumate, Nimesulide, Parecoxib, Talniflumate</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concurrent use of a COX-2 inhibitor was associated with a greater likelihood for hospitalization secondary to an upper GI bleed (OR=1.7 to 2.4), at a magnitude generally similar to that for a non-selective NSAID (OR=1.9), according to a case-control study of patients older than 66 years of age who were receiving continuous warfarin (n=361 hospitalized cases and 98,821 total warfarin users).<sup>1</sup> Other studies have concluded that COX-2 inhibitor use with warfarin was associated with a mild-to-moderate increase in the INR and/or risk for bleeding complications as compared to warfarin use without a COX-2 inhibitor.<sup>2,3,4</sup> Several case reports also conclude that concurrent use of a COX-2 inhibitor with warfarin is associated with an increased INR and/or clinical warfarin complications.<sup>5,6,7,8,9</sup> In contrast, there was no change in INR with concurrent celecoxib in a prospective study of 15 warfarin-treated patients who were given celecoxib (200 mg/day) for 5 weeks.<sup>10</sup><br><br>The specific mechanism(s) for this interaction is(are) unclear. Studies with celecoxib and etoricoxib suggest that these agents have relatively minimal effects on warfarin concentrations (i.e., increases in R- or S-warfarin of 10% or less),<sup>4,11</sup> suggesting that some additional mechanism(s) may be responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Battistella M, Mamdami MM, Juurlink DN, et al, “Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated with Nonselective NSAIDs or COX-2 Inhibitors,” <i>Arch Intern Med</i>, 2005, 165(2):189-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15668365\">[PubMed 15668365]</a></p>\n<p>2. Chung L, Chakravarty EF, Kearns P, et al, “Bleeding Complications in Patients on Celecoxib and Warfarin,” <i>J Clin Pharm Ther</i>, 2005, 30(5):471-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16164494\">[PubMed 16164494]</a></p>\n<p>3. Schaefer MG, Plowman BK, Morreale AP, et al, “Interaction of Rofecoxib and Celecoxib with Warfarin,” <i>Am J Health Syst Pharm</i>, 2003, 60(13):1319-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12901032\">[PubMed 12901032]</a></p>\n<p>4. Schwartz JI, Agrawal NG, Hartford AH, et al, “The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin,” <i>J Clin Pharmacol</i>, 2007, 47(5):620-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17442687\">[PubMed 17442687]</a></p>\n<p>5. Haase KK, Rojas-Fernandez CH, Lane L, et al, “Potential Interaction between Celecoxib and Warfarin,” <i>Ann Pharmacother</i>, 2000, 34(5):666-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10852097\">[PubMed 10852097]</a></p>\n<p>6. Mersfelder TL, Stewart LR, “Warfarin and Celecoxib Interaction,” <i>Ann Pharmacother</i>, 2000, 34:326-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917378\">[PubMed 10917378]</a></p>\n<p>7. Stoner SC, Lea JW, Dubisar BM, et al, “Possible International Normalized Ratio Elevation Associated with Celecoxib and Warfarin in an Elderly Psychiatric Patient,” <i>J Am Geriatr Soc</i>, 2003, 51(5):728-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12752860\">[PubMed 12752860]</a></p>\n<p>8. Malhi H, Atac B, Daly AK, et al, “Warfarin and Celecoxib Interaction in the Setting of Cytochrome P450 (CYP2C9) Polymorphism with Bleeding Complication,” <i>Postgrad Med J</i>, 2004, 80(940):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14970301\">[PubMed 14970301]</a></p>\n<p>9. Stading JA, Skrabal MZ, and Faulkner MA, “Seven Cases of Interactions Between Warfarin and Cyclo-Oxygenase-2 Inhibitors,” Am J Health-Syst Pharm, 2001, 58:2076-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11715832\">[PubMed 11715832]</a></p>\n<p>10. Dentali F, Douketis JD, Woods K, et al, “Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial,” <i>Ann Pharmacother</i>, 2006, 40(7-8):1241-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16804099\">[PubMed 16804099]</a></p>\n<p>11. Karim A, Tolbert D, Piergies A, et al, “Celecoxib Does Not Significantly Alter the Pharmacokinetics or Hypoprothrombinemic Effect of Warfarin in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2000, 40(6):655-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10868317\">[PubMed 10868317]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3408":"<p><b>Title</b> Vitamin K Antagonists / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving oral anticoagulants should be instructed to not initiate nonsteroidal anti-inflammatory agent (NSAID)-containing medicines without consulting his/her healthcare professional (nonacetylated salicylates might be safer alternatives). Acetaminophen is usually a good antipyretic and analgesic choice for patients taking oral anticoagulants. Monitor for increased signs and symptoms of bleeding if oral anticoagulant and an NSAID are used concomitantly.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal*, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin, Ketoprofen*, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid*, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Sulindac*, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin*, Zaltoprofen</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Most studies evaluating the effects of nonsteroidal anti-inflammatory agents (NSAIDs) on the hypoprothrombinemic effects of coumarin derivatives have demonstrated little to no effect.<sup>1,2,3,4,5,6,7,8,9,10</sup> A few case reports and small studies, however, have noted increases in prothrombin times (or other coagulation parameters) and bleeding episodes (typically minor).<sup>11,12,13,14,15,16,17,18</sup> Most nonselective NSAIDs (except possibly nabumetone) affect platelet aggregation.<sup>19</sup> The INR may not be altered during concomitant therapy with warfarin, though increased bleeding could occur.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Micot F, Ajdacic K, and Glaus L, “A Double-Blind Clinical Trial to Determine if an Interaction Exists Between Diclofenac Sodium and the Oral Anticoagulant Acenocoumarol (Nicoumalone),” <i>J Int Med Res</i>, 1975, 3:153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=162671\">[PubMed 162671]</a></p>\n<p>2. Serlin MJ, Mossman S, Sibeon RG, et al, “Interaction Between Diflunisal and Warfarin,” <i>Clin Pharmacol Ther</i>, 1980, 28:493. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408409\">[PubMed 7408409]</a></p>\n<p>3. Ermer JC, Hicks DR, Wheeler SC, et al, “Concomitant Etodolac Affects Neither the Unbound Clearance Nor the Pharmacologic Effect of Warfarin,” <i>Clin Pharmacol Ther</i>, 1994, 55:305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8143396\">[PubMed 8143396]</a></p>\n<p>4. Vesell ES, Passananti GT and Johnson AO, “Failure of Indomethacin and Warfarin to Interact in Normal Human Volunteers,” <i>J Clin Pharmacol</i>, 1975, 15:486-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1150903\">[PubMed 1150903]</a></p>\n<p>5. Mieszczak C and Winther K, “Lack of Interaction of Ketoprofen with Warfarin,” <i>Eur J Clin Pharmacol</i>, 1993, 44:205-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453969\">[PubMed 8453969]</a></p>\n<p>6. Homes EL, “Experimental Observations on Flufenamic, Mefenamic, and Meclofenamic Acids. IV. Toleration by Normal Human Subjects,” <i>Ann Phys Med</i>, 1966, 9(Suppl):36-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4895006\">[PubMed 4895006]</a></p>\n<p>7. Hilleman DE, et al, “Hypoprothrombinemic Effect of Nabumetone in Warfarin-Treated Patients,” <i>Pharmacotherapy</i>, 1993, 13:270.</p>\n<p>8. Slattery JT, Levy G, Jain A, et al, “Effect of Naproxen on the Kinetics of Elimination and Anticoagulant Activity of a Single Dose of Warfarin,” <i>Clin Pharmacol Ther</i>, 1979, 25:51-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=758243\">[PubMed 758243]</a></p>\n<p>9. Dahl SL, “Pharmacology, Clinical Efficacy, and Adverse Effects of Piroxicam, a New Nonsteroidal Anti-inflammatory Agent,” <i>Pharmacotherapy</i>, 1982, 2:80-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6765393\">[PubMed 6765393]</a></p>\n<p>10. Loftin JP and Vesell ES, “Interaction Between Sulindac and Warfarin: Different Result in Normal Subjects and in an Unusual Patient With a Potassium-Losing Renal Tubular Defect,” <i>J Clin Pharmacol</i>, 1979, 19(11-12):733-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=536470\">[PubMed 536470]</a></p>\n<p>11. Schulman S and Henriksson K, “Interaction of Ibuprofen and Warfarin on Primary Haemostasis, ” <i>Br J Rheumatol</i>, 1989, 28:46-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2783873\">[PubMed 2783873]</a></p>\n<p>12. Flessner MF and Knight H, “Prolongation of Prothrombin Time and Severe Gastrointestinal Bleeding Associated With Combined Use of Warfarin and Ketoprofen,” <i>JAMA</i>, 1988, 259:353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3257277\">[PubMed 3257277]</a></p>\n<p>13. Rhodes RS, Rhodes PJ, Klein C, et al, “A Warfarin-Piroxicam Drug Interaction,” <i>Drug Intell Clin Pharm</i>, 1985, 19:556. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4028961\">[PubMed 4028961]</a></p>\n<p>14. Koren JF, Cochran DL, and Janes RL, “Tolmetin-Warfarin Interaction,” <i>Am J Med</i>, 1987, 82:1278-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3605152\">[PubMed 3605152]</a></p>\n<p>15. Santopolo AC, “Tolmetin-Warfarin Interaction,”<i>Am J Med</i>, 1987, 82:1279-80.</p>\n<p>16. Marbet GA, Duckert F, Walter M, et al, “Interaction Study Between Phenprocoumon and Flurbiprofen,” <i>Curr Med Res Opin</i>, 1977, 5:26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=913120\">[PubMed 913120]</a></p>\n<p>17. Strickler BHCh and Delhez JL, “Interaction Between Flurbiprofen and Coumarins,” <i>Br Med J</i>, 1982, 285:812-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6811021\">[PubMed 6811021]</a></p>\n<p>18. Mersfelder TL and Stewart LR, “Warfarin and Celecoxib Interaction,” <i>Ann Pharmacother</i>, 2000, 34:326-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917378\">[PubMed 10917378]</a></p>\n<p>19. Brouwers JR and de Smet PA, “Pharmacokinetic-Pharmacodynamic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,” <i>Clin Pharmacokinet</i>, 1994, 27:462-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7882636\">[PubMed 7882636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3409":"<p><b>Title</b> Theophylline Derivatives / Beta-Blockers (Beta1 Selective)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker. Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.</p>\n<div>\n <p><b>Beta-Blockers (Beta1 Selective) Interacting Members</b> Acebutolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Celiprolol, Esmolol, Metoprolol, Nebivolol</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> All beta-blockers possess the potential to antagonize the bronchodilatory effects of theophylline. Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<br><br>Beta blockers may also decrease nonpulmonary effects of theophylline, but these interactions are typically of less clinical concern. Adverse cardiac and metabolic effects of high doses of theophylline (mediated by actions at beta receptors) have been reduced by beta-blocker treatment in several studies.<sup>1,2,3,4</sup> Additionally, chronotropic effects of lower doses of theophylline were abolished by atenolol coadministration in a study of patients with stable angina.<sup>5</sup> <br><br>Several beta-1 selective beta-blockers have been investigated for possible effects on theophylline disposition, following a study that showed a 37% decrease in theophylline clearance when administered concomitantly with propranolol (40 mg every 6 hours).<sup>6</sup> Of beta-1 selective agents, metoprolol, atenolol, and bisoprolol have all had no significant impact on theophylline disposition in clinical studies.<sup>6,7,8,9</sup> The interaction between theophylline and propranolol is likely due to propranolol inhibition of CYP1A2 and/or 3A4. No beta-blockers included in this monograph have been shown to substantially inhibit these enzymes, so no pharmacokinetic interactions are expected with these agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kempf J, Rusterholtz T, Ber C, et al, “Haemodynamic Study as Guideline for the Use of Beta Blockers in Acute Theophylline Poisoning,” <i>Intensive Care Med</i>, 1996, 22(6):585-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8814476\">[PubMed 8814476]</a></p>\n<p>2. Seneff M, Scott J, Friedman B, et al, “Acute Theophylline Toxicity and the Use of Esmolol to Reverse Cardiovascular Instability,” <i>Ann Emerg Med</i>, 1990, 19(6):671-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1971502\">[PubMed 1971502]</a></p>\n<p>3. Conrad KA and Prosnitz EH, “Cardiovascular Effects of Theophylline. Partial Attenuation by Beta-Blockade,” <i>Eur J Clin Pharmacol</i>, 1981, 21(2):109-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6122579\">[PubMed 6122579]</a></p>\n<p>4. Gaar GG, Banner W Jr and Laddu AR, “The Effects of Esmolol on the Hemodynamics of Acute Theophylline Toxicity,” <i>Ann Emerg Med</i>, 1987, 16(12):1334-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3688594\">[PubMed 3688594]</a></p>\n<p>5. Crea F, Pupita G, Galassi AR, et al, “Effects of Theophylline, Atenolol and Their Combination on Myocardial Ischemia in Stable Angina Pectoris,” <i>Am J Cardiol</i>, 1990, 66(17):1157-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2239717\">[PubMed 2239717]</a></p>\n<p>6. Conrad KA and Nyman DW, “Effects of Metoprolol and Propranolol on Theophylline Elimination,” <i>Clin Pharmacol Ther</i>, 1980, 28:463-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408406\">[PubMed 7408406]</a></p>\n<p>7. Corsi CM, Nafziger AN, Pieper JA, et al, “Lack of Effect of Atenolol and Nadolol on the Metabolism of Theophylline,” <i>Br J Clin Pharmacol</i>, 1990, 29:265-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2306421\">[PubMed 2306421]</a></p>\n<p>8. Cerasa LA, Bertino JS, Ludwig EA, et al, “Lack of Effect of Atenolol on the Pharmacokinetics of Theophylline,” <i>Br J Clin Pharmacol</i>, 1988, 26:800-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3242586\">[PubMed 3242586]</a></p>\n<p>9. Warrington SJ, Johnston A, Lewis Y, et al, “Bisoprolol: Studies of Potential Interactions with Theophylline and Warfarin in Healthy Volunteers,” <i>J Cardiovasc Pharmacol</i>, 1990, 16 Suppl 5:S164-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11527121\">[PubMed 11527121]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3410":"<p><b>Title</b> Theophylline Derivatives / Beta-Blockers (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If theophylline is being as a bronchodilator, consider avoiding the use of nonselective beta-blockers. Cardioselective agents would be preferred, although higher doses of these agents might also antagonize the effects of theophylline. Monitor for symptoms of reduced theophylline efficacy during concomitant use with any beta-blocker. Ophthalmic beta-blockers are likely of little concern.</p>\n<div>\n <p><b>Beta-Blockers (Nonselective) Interacting Members</b> Arotinolol, Carteolol (Ophthalmic), Carvedilol, Labetalol, Levobunolol, Metipranolol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The clearance of theophylline was decreased by 37% in 9 normal subjects when administered concomitant with propranolol (40 mg every 6 hours).<sup>1</sup> Metoprolol was not found to significantly affect theophylline in the same study. Similar results have been elsewhere reported with increasing doses of propranolol being associated with greater effects on theophylline clearance.<sup>2,3</sup> The pharmacokinetics of theophylline do not appear to be affected by either atenolol or nadolol.<sup>4,5</sup> All beta-blockers possess the potential to antagonize the bronchodilatory effects of theophylline. Selective agents are less likely to cause problems. Some beta-blockers (eg, propranolol) appear to be able to reduce theophylline metabolism (probably reducing demethylation). The clinical impact of this effect on theophylline is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Conrad KA and Nyman DW, “Effects of Metoprolol and Propranolol on Theophylline Elimination,” <i>Clin Pharmacol Ther</i>, 1980, 28:463-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408406\">[PubMed 7408406]</a></p>\n<p>2. Miners JO, Wing LM, Lillywhite KJ, et al, “Selectivity and Dose-Dependency of the Inhibitory Effect of Propranolol on Theophylline Metabolism in Man,” <i>Br J Clin Pharmacol</i>, 1985, 20:219-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4041342\">[PubMed 4041342]</a></p>\n<p>3. Lombardi TP, Bertino JS Jr, Goldberg A, et al, “The Effects of a Beta-2 Selective Adrenergic Agonist and a Beta-Nonselective Antagonist on Theophylline Clearance,” <i>Drug Intell Clin Pharm</i>, 1987, 27(7):523-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2888791\">[PubMed 2888791]</a></p>\n<p>4. Corsi CM, Nafziger AN, Pieper JA, et al, “Lack of Effect of Atenolol and Nadolol on the Metabolism of Theophylline,” <i>Br J Clin Pharmacol</i>, 1990, 29:265-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2306421\">[PubMed 2306421]</a></p>\n<p>5. Cerasa LA, Bertino JS, Ludwig EA, et al, “Lack of Effect of Atenolol on the Pharmacokinetics of Theophylline,” <i>Br J Clin Pharmacol</i>, 1988, 26:800-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3242586\">[PubMed 3242586]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3411":"<p><b>Title</b> LamoTRIgine / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Lamotrigine prescribing information contains specific dosing information for patients who are using concurrent barbiturates (or other enzyme inducing antiepileptic drugs). There are separate guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Dosing guidelines for adjusting lamotrigine doses upon discontinuation of a barbiturate are also contained in the prescribing information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> The manufacturer reports that the addition of phenobarbital to existing lamotrigine therapy results in an estimated 40% decrease in steady state serum lamotrigine concentrations.<sup>1</sup> Specific dosing guidelines for use of lamotrigine during concomitant therapy are contained in the lamotrigine prescribing information, as are guidelines for adjusting lamotrigine dosing if concurrent phenobarbital is discontinued.<br><br>This interaction is though to be the result of phenobarbital-mediated induction of lamotrigine glucuronidation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3412":"<p><b>Title</b> LamoTRIgine / Primidone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of lamotrigine has published extensive dosage adjustment guidelines in the approved labeling when the drug is added to an enzyme-inducing antiepileptic drug; refer to the labeling for additional information. Monitor for decreased serum concentrations/effects of lamotrigine if primidone is initiated/dose increased, or increased effects if primidone is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Lamotrigine prescribing information states that addition of primidone to existing lamotrigine therapy results in an approximately 40% decrease in steady state serum lamotrigine concentrations.<sup>1</sup> Detailed dosing guidelines for lamotrigine during primidone coadministration are given in lamotrigine prescribing information. A population pharmacokinetic study using data from epileptic patients estimated that lamotrigine clearance was increased by approximately 80% during concomitant primidone treatment, based on nonlinear multiple effects modeling.<sup>2</sup><br><br>The likely mechanism of this interaction is induction of lamotrigine glucuronidation by phenobarbital, a metabolite of primidone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline, March 2009.</p>\n<p>2. Rivas N, Buelga DS, Elger CE, et al, “Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy,” <i>Ther Drug Monit</i>, 2008, 30(4):483-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18641550\">[PubMed 18641550]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3413":"<p><b>Title</b> Propranolol / Flecainide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of Flecainide. Flecainide may increase the serum concentration of Propranolol. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a study of 10 healthy volunteers, the AUCs of flecainide (200 mg orally twice daily) and propranolol (80 mg orally 3 times/day) were increased 20% and 30%, respectively, when administered concurrently.<sup>1</sup> <br><br>The mechanism of this interaction is unknown. Flecainide and propranolol are both substrates of CYP2D6 and may competitively (or noncompetitively) inhibit one another's metabolism via this pathway. Combined pharmacodynamic effects on heart rate, PR interval, and QTc interval have been reported, but the clinical importance of these effects is unknown.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Holtzman JL, Kvam DC, Berry DA, et al, “The Pharmacodynamic and Pharmacokinetic Interaction of Flecainide Acetate With Propranolol: Effects on Cardiac Function and Drug Clearance,” <i>Eur J Clin Pharmacol</i>, 1987, 33:97-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3121353\">[PubMed 3121353]</a></p>\n<p>2. Lewis GP and Holtzman JL, “Interaction of Flecainide with Digoxin and Propranolol,” <i>Am J Cardiol</i>, 1984, 53(5):52B-57B. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6695818\">[PubMed 6695818]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3416":"<p><b>Title</b> Protease Inhibitors / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may decrease the serum concentration of Delavirdine. Delavirdine may increase the serum concentration of Protease Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consult product labeling if a protease inhibitor and delavirdine are used concomitantly as empiric dosage adjustments may be recommended to reduce the risk of toxicity. Monitor for toxic effects of protease inhibitors if delavirdine is initiated/dose increased, or decreased effects if delavirdine is discontinued/dose decreased.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir*, Lopinavir, Nelfinavir*, Ritonavir, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to data described in delavirdine prescribing information, delavirdine has the potential to increase the serum concentrations of protease inhibitors. When combined with delavirdine (400mg TID), indinavir AUC at a dose of 400mg TID was comparable to the AUC without delavirdine of 800mg TID.<sup>1</sup> With delavirdine plus indinavir 600mg TID, indinavir AUC was 53% higher than that with indinavir 800mg TID alone. Minimum concentrations (Cmin) of indinavir 400mg TID and 600mg TID were 118% and 298% higher with delavirdine, respectively, as compared to indinavir 800mg TID alone. With nelfinavir 750mg TID, combination therapy with delavirdine 400mg TID was associated with 107% and 136% increases in nelfinavir AUC and Cmin, respectively, versus nelfinavir alone.<sup>1</sup> Concentrations of the active nelfinavir metabolite were significantly decreased with delavirdine coadministration. Saquinavir AUC and Cmin were increased by 121% and 199%, respectively, following saquinavir 1000mg TID plus delavirdine 400mg TID, versus saquinavir 1200mg TID alone.<sup>1</sup> In a separate report, the AUC of amprenavir (1200mg single dose) was increased 4-fold in 12 normal subjects when administered following a 6 day course of delavirdine (600mg BID).<sup>2</sup> In the same report, concomitant administration of these two drugs in 12 normal subjects (600mg BID of each drug x 7 days) produced a 30% overall increase in amprenavir AUC (vs. 1200mg BID alone). Dosage adjustments of protease inhibitors (sometimes empiric per manufacturer labeling) may be necessary.<br><br>In contrast, the protease inhibitors indinavir and saquinavir appear to have little effect on delavirdine pharmacokinetics.<sup>1</sup> Concurrent nelfinavir has been associated with a 31% reduction in delavirdine AUC and a 33% reduction in delavirdine Cmin.<sup>1</sup> The manufacturer of amprenavir also reports a reduction in delavirdine AUC (61%) following 10 days of concomitant administration.<sup>3</sup> In a separate report, combination delavirdine and amprenavir in 12 normal subjects (600mg BID of each drug x 7 days) resulted in a 50% decrease in delavirdine AUC.<sup>2</sup><br><br>The protease inhibitors and delavirdine possess CYP inhibitory activity, especially with CYP2D6 and CYP3A isoenzymes. These agents are also substrates for these same enzymes. This would explain the noted increases in protease inhibitor concentrations. The reason for decreased delavirdine concentrations (ie, increased clearance) in conjunction with amprenavir and nelfinavir therapy is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rescriptor (delavirdine). New York, NY: Pfizer Inc, June 2006.</p>\n<p>2. Tran JQ, Petersen C, Garrett M, et al, “Pharmacokinetic Interaction Between Amprenavir and Delavirdine: Evidence of Induced Clearance by Amprenavir,” <i>Clin Pharmacol Ther</i>, 2002, 72(6):615-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12496743\">[PubMed 12496743]</a></p>\n<p>3. Prescribing information. Agenerase (amprenavir). Research Triangle Park, NC: GlaxoSmithKlin, 2002.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3419":"<p><b>Title</b> Succinylcholine / Echothiophate Iodide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Echothiophate Iodide may increase the serum concentration of Succinylcholine. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.</p> \n<p><b>Discussion</b> Case reports of prolonged apnea from succinylcholine in patients receiving echothiophate iodide eye drops have been published.<sup>1,2,3</sup> Echothiophate iodide eye drops, even in doses as low as two drops of a 0.06% solution in each eye 3 times/week, can reduce pseudocholinesterase activity as much as 50%.<sup>4</sup> <br><br>Ths likely mechanism of this interaction is echothiophate inhibition of pseudocholinesterase mediated succinylcholine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gesztes T, “Prolonged Apnoea After Suxamethonium Injection Associated With Eye Drops Containing an Anticholinesterase Agent,” <i>Br J Anaesth</i>, 1966, 38:408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5939140\">[PubMed 5939140]</a></p>\n<p>2. Pantuck EJ, “Ecothiopate Iodide Eye Drops and Prolonged Response to Suxamethonium,” <i>Br J Anaesth</i>, 1966, 38:406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5939139\">[PubMed 5939139]</a></p>\n<p>3. Mone JG and Mathie WE, “Qualitative Defects of Pseudocholinesterase Activity,” <i>Anaesthesia</i>, 1967, 22:55-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4959505\">[PubMed 4959505]</a></p>\n<p>4. Eilderton TE, Farmati O, and Zsigmond EK, “Reduction in Plasma Cholinesterase Levels After Prolonged Administration of Echothiophate Iodide Eyedrops,” <i>Can Anaesth Soc J</i>, 1968, 15:291-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5658433\">[PubMed 5658433]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3420":"<p><b>Title</b> Succinylcholine / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n</div> \n<p><b>Discussion</b> Two case reports describe prolonged succinylcholine neuromuscular blockade in patients given acetylcholinesterase inhibitors (AChEIs). In one, a 51 year old patient experienced prolonged paralysis when a single dose of neostigmine was given following succinylcholine.<sup>1</sup> In the other, a 72 year old treated with donepezil experienced prolonged neuromuscular blockade when succinylcholine was administered during an intubation procedure.<sup>2</sup><br><br>Succinylcholine is metabolized to succinylmonocholine, and then to succinic acid and choline, by plasma cholinesterase.<sup>3</sup> AChEIs inhibit plasma cholinesterase, and may thereby increase succinylcholine exposure and prolong neuromuscular blocking effects. <br><br>Conversely, effects of nondepolarizing neuromuscular blocking agents (NonDNMBAs) can often be reduced or eliminated by AChEIs. AChEIs inhibit acetylcholine hydrolysis and increase acetylcholine concentrations in the neuromuscular junction, which can overcome competitive inhibition of neuromuscular endplate receptors by NonDNMBAs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ramirez JG, Sprung J, Keegan MT, et al, “Neostigmine-Induced Prolonged Neuromuscular Blockade in a Patient With Atypical Pseudocholinesterase,” <i>J Clin Anesth</i>, 2005, 17(3):221-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15896593\">[PubMed 15896593]</a></p>\n<p>2. Crowe S and Collins L, “Suxamethonium and Donepezil: a Cause of Prolonged Paralysis,” <i>Anesthesiology</i>, 2003, 98(2):574-575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12552219\">[PubMed 12552219]</a></p>\n<p>3. Prescribing Information. Quelicin (succinylcholine). Lake Forest, IL: Hospira, Mar 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3421":"<p><b>Title</b> Mycophenolate / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Mycophenolate. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exception</b> Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The C<sub>max</sub> and AUC of mycophenolate (2 g single dose) were decreased 33% and 17%, respectively, in 10 patients when administered simultaneously with aluminum hydroxide/magnesium hydroxide.<sup>1</sup> Mycophenolate apparently binds to aluminum and/or magnesium ions in the GI tract, forming a less soluble/absorbable complex. The manufacturer recommends separating doses to minimize the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cellcept (mycophenolate). Nutley, NJ: Roche Laboratories, 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3422":"<p><b>Title</b> Mycophenolate / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of magnesium salts and mycophenolate are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Mycophenolate. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> In a study cited in mycophenolate prescribing information, the maximum concentration and AUC (a measure of drug exposure) of mycophenolate (2 g single dose) were decreased 33% and 17%, respectively, in 10 rheumatoid arthritis patients when administered simultaneously with aluminum hydroxide/magnesium hydroxide (1200 mg/600 mg four times daily for 2 days).<sup>1,2</sup> <br><br>Mycophenolate may bind to aluminum and/or magnesium ions in the GI tract, forming a less soluble/absorbable complex. The manufacturer of mycophenolate recommends separating doses to minimize the interaction. The same precautions would seem prudent when administering nonantacid, oral magnesium supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cellcept (mycophenolate mofetil). South San Francisco, CA: Genentech USA, Inc., February 2010.</p>\n<p>2. Bullingham R, Shah J, Goldblum R, et al, “Effects of Food and Antacid on the Pharmacokinetics of Single Doses of Mycophenolate Mofetil in Rheumatoid Arthritis Patients,” <i>Br J Clin Pharmacol</i>, 1996, 41(6):513-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8799515\">[PubMed 8799515]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3424":"<p><b>Title</b> Rifamycin Derivatives / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of rifamycin derivatives (especially rifabutin) if a macrolide antibiotic is initiated/dose increased, or decreased effects if a macrolide antibiotic is discontinued/dose decreased. Monitor for reduced effects of macrolides (and telithromycin, a ketolide) if a rifamycin is initiated/dose increased.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin*, Erythromycin (Systemic), Telithromycin*<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*<br><b>Exception</b> Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports. Patients have developed increased serum rifabutin concentrations, and signs/symptoms of associated toxicity (eg, elevated hepatic enzymes, leukopenia, thrombocytopenia, and uveitis) when concomitantly administered with clarithromycin.<sup>1,2</sup> Rifabutin is a CYP3A4 substrate, and clarithromycin is both a substrate and an inhibitor of this same isoenzyme. Reduced rifabutin metabolism is expected. Several other macrolides share these CYP effects. The ability of these agents to affect rifampin, a potent CYP3A4 inducer, is unknown. Rifapentine metabolism is mediated by esterase activity, and thus would not likely be affected by other drugs.<br><br>The AUC of telithromycin, a ketolide antibiotic, was decreased 86% when coadministered with rifampin.<sup>3</sup> Rifampin induction of CYP3A4 enzymes is the probable mechanism of this pharmacokinetic effect. A reduction in the efficacy of telithromycin seems likely. A similar effect is possible with most macrolide antibiotic, except possibly azithromycin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuper JJ and d'Aprile M, “Drug-Drug Interactions of Clinical Significance in the Treatment of Patients With <i>Mycobacterium avium</i> Complex Disease,” <i>Clin Pharmacokinet</i>, 2000, 39(3):203-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11020135\">[PubMed 11020135]</a></p>\n<p>2. Hafner R, Bethel J, Power M, et al, “Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers,” <i>Antimicrob Agents Chemother</i>, 1998, 42(3):631-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9517944\">[PubMed 9517944]</a></p>\n<p>3. Ketec [package insert]. Laval, Quebec: Aventis Pharma Inc, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3425":"<p><b>Title</b> RifAMPin / Pyrazinamide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pyrazinamide may enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Rifampin-pyrazinamide (RIF-PZA) continues to be an option for the treatment of latent tuberculosis infection in patients at high risk of developing active TB who are unlikely to complete the preferred treatment (9 months of isoniazid). However, the CDC, along with the American Thoracic Society, recommends that this option generally not be offered.<sup>3</sup> Monitor for liver toxicity in patients receiving concomitant rifampin and pyrazinamide, particularly in patients with liver disease, those receiving other medications associated with liver toxicity or a history of alcoholism (even if alcohol use is discontinued during treatment).<sup>1</sup> Careful monitoring of hepatic function is recommended for all treatment regimens, since all recommended regimens have been associated with some potential for hepatotoxicity.</p> \n<p><b>Discussion</b> The Centers for Disease Control (CDC) has described 21 cases of severe liver injury associated with a 2-month regimen of rifampin and pyrazinamide (RIF-PZA) used for the treatment of latent tuberculosis infection (LTBI).<sup>1,2</sup> Five of the 21 cases were fatal. A similar study documented 50 cases of severe liver injury resulting in 12 fatalities for patients receiving this regimen between October 1998 and March 2004.<sup>4</sup> Both agents are recognized to be associated with liver toxicity (pyrazinamide less than rifampin). Their additive (possibly synergistic) effects likely account for identified reactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Centers for Disease Control and Prevention (CDC). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations --- United States, 2001. <i>MMWR Morb Mortal Wkly Rep</i>. 2001;50(34):733-735. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11787580\">[PubMed 11787580]</a></p>\n<p>2. Centers for Disease Control and Prevention (CDC). Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection --- New York and Georgia, 2000. <i>MMWR Morb Mortal Wkly Rep</i>. 2001;50(15):289-291. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11330495\">[PubMed 11330495]</a></p>\n<p>3. Centers for Disease Control and Prevention (CDC). Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection --- United States, 2003. <i>MMWR Morb Mortal Wkly Rep</i>. 2003;52(31):735-739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12904741\">[PubMed 12904741]</a></p>\n<p>4. Ijaz K, Jereb JA, Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. <i>Clin Infect Dis</i>. 2006;42(3):346-355. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16392079\">[PubMed 16392079]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3433":"<p><b>Title</b> Benzodiazepines (metabolized by glucuronidation) / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may increase the metabolism of Benzodiazepines (metabolized by glucuronidation). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Benzodiazepines (metabolized by glucuronidation) Interacting Members</b> LORazepam*, Oxazepam*, Temazepam*</p>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Oral contraceptives have been reported to increase the clearance of benzodiazepines that undergo glucuronidation.<sup>1</sup> A second report failed to identify any significant effects.<sup>2</sup> Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stoehr GP, Kroboth PD, Juhl RP, et al, “Effect of Oral Contraceptives on Triazolam, Temazepam, Alprazolam, and Lorazepam Kinetics,” <i>Clin Pharmacol Ther</i>, 1984, 36:683-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6149030\">[PubMed 6149030]</a></p>\n<p>2. Abernethy DR, Greenblatt DJ, Ochs HR, et al, “Lorazepam and Oxazepam Kinetics in Women on Low-Dose Oral Contraceptives,” <i>Clin Pharmacol Ther</i>, 1983, 33:628-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6132698\">[PubMed 6132698]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3441":"<p><b>Title</b> Acyclovir-Valacyclovir / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Acyclovir-Valacyclovir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, subjects were given 1,000 mg of valacyclovir and assigned to1 of 4 treatment arms; probenecid (1000 mg), cimetidine (800 mg), both probenecid and cimetidine, or no concomitant treatment (control group).<sup>1</sup> The maximum serum concentration of acyclovir (the active ingredient of the prodrug valacyclovir) was unchanged and the AUC increased 23% in patients receiving cimetidine compared to the control group. Product labeling for valacyclovir recommends no dose adjustment when valacyclovir is co-administered with cimetidine.<sup>2</sup><br><br>Although the mechanism of this potential interaction has not been conclusively established, cimetidine inhibition of the active renal tubular secretion of acyclovir has been proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. <i>Antimicrob Agents Chemother</i>. 2002;46(2):458-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11796358\">[PubMed 11796358]</a></p>\n<p>2. <i>Valtrex</i> (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3442":"<p><b>Title</b> Zidovudine / Acyclovir-Valacyclovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for lethargy and fatigue in patients receiving concomitant zidovudine and acyclovir or valacyclovir. The symptoms may present in less than 1 hour of initiating concomitant therapy.</p>\n<div>\n <p><b>Acyclovir-Valacyclovir Interacting Members</b> Acyclovir (Systemic), ValACYclovir*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One case report describes development of severe lethargy and fatigue within 1 hour of initiating zidovudine in a man receiving acyclovir.<sup>1</sup> Symptoms subsided when acyclovir was discontinued, and redeveloped when acyclovir was restarted. In a clinical study severe somnolence was reported in 2% and 4% of patients receiving the combination for AIDS and AIDS related complex, respectively, compared to 1% and 0%, respectively, among patients receiving zidovudine alone.<sup>2</sup><br><br>The mechanism of this possible interaction is unclear. In two clinical studies, there was no apparent impact of coadministration on the pharmacokinetic profile of either drug.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach MC, “Possible Drug Interaction During Therapy With Azidothymidine and Acyclovir for AIDS,” <i>N Engl J Med</i>, 1987, 317:547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3468354\">[PubMed 3468354]</a></p>\n<p>2. Pedersen C, Cooper DA, Brun-Vezinet F, et al, “The Effect of Treatment with Zidovudine with or without Acyclovir on HIV p24 Antigenaemia in Patients with AIDS or AIDS-Related Complex,” <i>AIDS</i>, 1992, 6(8):821-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1418778\">[PubMed 1418778]</a></p>\n<p>3. Tartaglione TA, Collier AC, Opheim K, et al, “Pharmacokinetic Evaluations of Low- and High-Dose Zidovudine Plus High-Dose Acyclovir in Patients With Symptomatic Human Immunodeficiency Virus Infection,” <i>Antimicrob Agents Chemother</i>, 1991, 35:2225-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1803995\">[PubMed 1803995]</a></p>\n<p>4. Hollander H, Lifson AR, Maha M, et al, “Phase I Study of Low-Dose Zidovudine and Acyclovir in Asymptomatic Human Immunodeficiency Virus Seropositive Individuals,” <i>Am J Med</i>, 1989, 87(6):628-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2574006\">[PubMed 2574006]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3443":"<p><b>Title</b> Deferoxamine / Ascorbic Acid</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Ascorbic acid may be used at doses of 200 mg/day or less under certain circumstances. Avoid ascorbic acid doses greater than 200 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ascorbic Acid may enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid ascorbic acid doses greater than 200 mg/day in patients receiving deferoxamine, due to a potential risk of diminished left ventricular function. Ascorbic acid doses 200 mg/day or less may be administered to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.</p> \n<p><b>Discussion</b> Ascorbic acid has been administered concomitantly with deferoxamine in some patients to increase the excretion of iron. However, prescribing information for deferoxamine recommends avoiding its use with ascorbic acid doses exceeding 200 mg/day.<sup>1</sup> Reports have been published of patients receiving 500 mg/day of ascorbic acid who experienced clinically important, transient deterioration of left ventricular function.<sup>2,3,4,5</sup><br><br>In contrast to the above cases, in a clinical study of 16 patients receiving iron chelation therapy with deferoxamine, 10 of the patients were given supplemental ascorbic acid (200 mg daily) 9 - 12 months after starting therapy, 9 of whom actually experienced increases in left ventricular ejection fraction (LVEF).<sup>6</sup> The one additional patient whose LVEF decreased while on ascorbic acid supplementation had pre-existing ischemic heart disease.<br><br>The reason for these effects has not been investigated. One group proposed that enhanced iron release from reticuloendothelial cells at higher ascorbic acid doses could enhance cardiac oxidative stress.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Desferal (deferoxamine mesylate). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p>2. Nienhaus AW, “Vitamin C and Iron,” <i>N Engl J Med</i>, 1981, 304:170-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442737\">[PubMed 7442737]</a></p>\n<p>3. Cohen A, Cohen U, and Schwartz E, “Scurvy and Altered Iron Stores in Thalassaemia Major,” <i>N Engl J Med</i>, 1981, 304(3):158-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442735\">[PubMed 7442735]</a></p>\n<p>4. Henry W, “Echocardiographic Evaluation of the Heart in Thalassaemia Major,” <i>Ann Intern Med</i>, 1978:892-4.</p>\n<p>5. Schafer AI, Rabinowe S, LeBoff MS, et al, “Long-term Efficacy of Deferoxamine Iron Chelation Therapy in Patients With Acquired Transfusional Iron Overload,” <i>Arch Intern Med</i>, 1985, 145(7):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3925909\">[PubMed 3925909]</a></p>\n<p>6. Jensen P, Olsen N, Bagger J, et al. “Cardiac Function During Iron Chelation Therapy in Adult Non-thalassaemic Patients With Transfusional Iron Overload,” <i>Eur J Haematol</i>, 1997, 59(4):221-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9338620\">[PubMed 9338620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3444":"<p><b>Title</b> Monoamine Oxidase Inhibitors / BusPIRone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> BusPIRone may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, blood pressure elevations been reported. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of buspirone with monoamine oxidase inhibitors due to a risk of blood pressure elevation.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The manufacturer of buspirone states “there have been reports of the occurrence of elevated blood pressure when [buspirone] has been added to a regimen including an MAOI.”<sup>1</sup> The manufacturer recommends that the agents not be used concomitantly.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Buspar (buspirone). Princeton, NJ: Bristol-Myers Squibb Company, November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3445":"<p><b>Title</b> CloZAPine / Nefazodone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nefazodone may decrease the metabolism of CloZAPine. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased clozapine effects/toxicities if combined with nefazodone.</p> \n<p><b>Discussion</b> Serum clozapine concentrations increased 75% in a therapy-stable patient within 2 weeks of initiating nefazodone (200 mg/day for 1 week, then 300 mg/day thereafter).<sup>1</sup> By the end of the second week of concomitant therapy the patient complained of anxiety and dizziness and mild hypotension was noted. Symptoms resolved within 1 week of reducing the dose of nefazodone to 200 mg/day.<sup>1</sup><br><br>In contrast, 6 patients on stable clozapine therapy who were administered nefazodone (100 mg twice daily for 1 week, then 200 mg twice daily for 2 weeks) had a 4% and 16% increase in clozapine and norclozapine levels, respectively.<sup>2</sup> <br><br>The mechanism of this interaction is unknown, but nefazodone inhibition of CYP1A2 or CYP3A4, enzymes responsible for clozapine metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khan AY, Preskorn S. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. <i>J Clin Psychiatry</i>. 2001;62(5):375-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11411823\">[PubMed 11411823]</a></p>\n<p>2. Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. <i>Int Clin Psychopharmacol</i>. 1999;14(3):185-187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435773\">[PubMed 10435773]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3446":"<p><b>Title</b> RisperiDONE / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of risperidone (eg, extrapyramidal symptoms) if an interacting SSRI is initiated/dose increased, or decreased effects if an SSRI is discontinued/dose decreased. Fluoxetine and paroxetine of are most concern. Citalopram, escitalopram, and sertraline may have minor effects. Fluvoxamine will not likely affect risperidone.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, PARoxetine*, Sertraline, Vilazodone, Vortioxetine<br><b>Exception</b> FluvoxaMINE</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mean plasma risperidone concentrations (based on 4-8 mg/day) increased nearly fivefold in 10 patients after 2 weeks of concomitant therapy with paroxetine (20 mg/day).<sup>1</sup> The mean ratio of risperidone:9-hydroxyrisperidone (its active metabolite) was also increased after 4 weeks of concomitant therapy. One patient developed Parkinsonism during the second week of concomitant therapy. The likely mechanism of this interaction is paroxetine inhibition of CYP2D6 isoenzyme metabolism of risperidone. Fluoxetine inhibits CYP2D6 to a similar extent, whereas vilazodone is a moderate inhibitor and citalopram, escitalopram, and sertraline are weaker. Fluvoxamine would not be expected to significantly affect risperidone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spina E, Avenoso A, Facciola G, et al, “Plasma Concentrations of Risperidone and 9-hydroxyrisperidone During Combined Treatment With Paroxetine,” <i>Ther Drug Monit</i>, 2001, 23(3):223-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11360029\">[PubMed 11360029]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3447":"<p><b>Title</b> Thyroid Products / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Onset</b> Delayed (Sequence Important) <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations (free thyroxine)/therapeutic effects of thyroid products if an estrogen derivative is initiated/dose increased, or increased effects if an estrogen derivative is discontinued/dose decreased. Consider measuring thyrotropin concentrations approximately 12 weeks after initiating estrogen therapy.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum free-thyroxine concentrations were decreased by 18% in 25 thyroid product-stable patients 12 weeks after initiating conjugated estrogen therapy (0.625 mg/day).<sup>1</sup> Increased doses of thyroxine was needed to maintain adequate serum free-thyroxine concentrations. Total serum thyroxine and thyroxine-binding globulin (TBG) concentrations were increased 30% and 54%, respectively. It appears as though estrogen therapy increased serum TBG concentrations, thus decreasing serum free-thyroxine concentrations. In a database analysis, median serum TSH concentrations were 0.08 mIU/L greater in the 6 months following estrogen initiation compared to the year prior in 258 patients receiving stable levothyroxine doses.<sup>2</sup> TSH concentrations following estrogen initiation increased by at least 5 mIU/L in 4.3% of patients, and decreased by at least 5 mIU/L in 1.6% of patients.<br><br>Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Arafah BM, “Increased Need for Thyroxine in Women With Hypothyroidism During Estrogen Therapy,” <i>N Engl J Med</i>, 2001, 344(23):1743-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11396440\">[PubMed 11396440]</a></p>\n<p>2. A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS) [published online July 17, 2014]. <i>Clin Endocrinol (Oxf)</i>. doi:10.1111/cen.12559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25040647\">[PubMed 25040647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3448":"<p><b>Title</b> Didanosine / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of Didanosine. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of didanosine with allopurinol is contraindicated.</p> \n<p><b>Discussion</b> The mean AUC of didanosine (400mg x1) increased 113% in healthy volunteers pre-treated with a 7-day course of allopurinol (300mg/day).<sup>1</sup> Similarly, didanosine (200mg x1) AUC increased more than 300% in subjects with renal impairment pre-treated with allopurinol (300mg/day).<sup>1</sup> This increased exposure to didanosine could lead to a greater risk of toxicity; consequently, didanosine prescribing information recommends avoiding concurrent use of didanosine with allopurinol.<sup>1</sup><br><br>The mechanism of this interaction appears to be inhibition of didanosine metabolism via a direct action of allopurinol (i.e., inhibition of xanthine oxidase-mediated metabolism) and/or an indirect action (i.e., allopurinol related accumulation of hypoxanthine leading to decreased purine nucleoside phosphorylase-mediated didanosine metabolism).<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Videx EC (didanosine). Princeton, NJ: Bristol-Myers Squibb, September 2008.</p>\n<p>2. Back DJ, Ormesher S, Tjia JF, et al, “Metabolism of 2',3'-dideoxyinosine (ddI) in Human Blood,” <i>Br J Clin Pharmacol</i>, 1992, 33(3):319-22. [PMID: 1576055]</p>\n<p>3. Ray AS, Olson L, Fridland A, “Role of Purine Nucleoside Phosphorylase in Interactions Between 2',3'-dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2004, 48(4):1089-95. [PMID: 15047506]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3449":"<p><b>Title</b> Ritonavir / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefloquine may decrease the serum concentration of Ritonavir. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Steady state AUC and C<sub>max</sub> of ritonavir (200 mg twice daily for 7 days) were decreased 31% and 36%, respectively, in 12 normal subjects when administered concomitant with the last dose of a 4-week course of mefloquine (250 mg/week, preceded by a 3-day course at the same dose).<sup>1</sup> An evaluation of the effects of mefloquine on a single dose of ritonavir failed to show any pharmacokinetic changes.<sup>1</sup> CYP3A4 effects and altered protein binding were mechanisms ruled out by the authors. Ritonavir is reported to be a p-glycoprotein substrate, and mefloquine a p-glycoprotein inhibitor. These characteristics would lead one to predict increased, not decreased, ritonavir concentrations. Therefore, a mechanism for this apparent interaction remains unclear.<br><br>Additional data from the same report demonstrates that ritonavir has little, if any, effect on mefloquine pharmacokinetics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khaliq Y, Gallicano K, Tisdale C, et al, “Pharmacokinetic Interaction Between Mefloquine and Ritonavir in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 2001, 51(6):591-600. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422019\">[PubMed 11422019]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3450":"<p><b>Title</b> Protease Inhibitors / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of other Protease Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Dosage adjustments of one or both agents when used in the following combinations are recommended by the manufacturers (consult the product package insert for specific dosage recommendations): Ritonavir in combination with any other protease inhibitor; indinavir/nelfinavir; and nelfinavir/saquinavir. Ritonavir is intentionally used in combination with some agents to increase the serum concentrations of the latter agents. Concurrent use of tipranavir/ritonavir or atazanavir/ritonavir combinations with other protease inhibitors is not recommended. Concomitant use of darunavir/cobicistat with protease inhibitors that require boosting should be avoided. Both atazanavir and indinavir are associated with indirect (unconjugated) hyperbilirubinemia; their concurrent use is contraindicated. Safe and appropriate dosing for the use of darunavir/ritonavir in combination with indinavir has not been established. Monitor for toxic effects of protease inhibitors during concomitant use.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir*, Indinavir*, Lopinavir, Nelfinavir*, Ritonavir*, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Protease inhibitors are substrates of CYP3A4. They also inhibit, to varying degrees, this same isoenzyme. As such, their concomitant use can result in increased serum concentrations of one or both agents being administered, depending on the extent of CYP3A4 effects.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Empiric dosage adjustments or avoidance of certain combinations is recommended to reduce the risk of toxicity. Concomitant use of ritonavir with some other protease inhibitors (eg, darunavir, fosamprenavir, saquinavir,and tipranavir) takes advantage of this interaction, resulting in increased and adequate serum concentrations of the latter agents.<sup>1,2,3,4,5</sup> Concomitant administration of fosamprenavir and atazanavir results in no change in amprenavir concentrations and a modest 20% decrease in atazanavir concentrations.<sup>3</sup> Combination therapy with atazanavir 400mg and saquinavir 1200mg (both once daily), with tenofovir (300mg daily) and a nucleoside analogue reverse transcriptase inhibitor failed to demonstrate adequate efficacy; appropriate dosing for the use of atazanavir and saquinavir together has not been identified.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 2004.</p>\n<p>2. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, June 2006.</p>\n<p>3. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, 2003.</p>\n<p>4. Prescribing information. Invirase (saquinavir). Nutley, NJ: Hoffman La-Roche Inc, 2003.</p>\n<p>5. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 10/2007.</p>\n<p>6. Prescribing information. Fortovase (saquinavir). Nutley, NJ: Hoffman La-Roche Inc, 2003.</p>\n<p>7. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co Inc, 2004.</p>\n<p>8. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, 2003.</p>\n<p>9. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals Inc, 2004.</p>\n<p>10. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, March 2008.</p>\n<p>11. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3452":"<p><b>Title</b> Serotonin Modulators / Serotonin Modulators</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Serotonin Modulators may enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of agents that enhance serotonin activity should be undertaken with great caution. Patients should be monitored for the development of serotonin toxicity/serotonin syndrome during such therapy.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exceptions</b> Nicergoline, Tedizolid</p>\n</div> \n<p><b>Discussion</b> Many drugs possess an ability to enhance serotonin activity, and are so used in a variety of disease states. The concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. These toxic effects may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>2. Sternbach H. The serotonin syndrome. <i>Am J Psychiatry</i>. 1991;148(6):705-713. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3454":"<p><b>Title</b> Dofetilide / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of dofetilide contraindicates concomitant use with ketoconazole. Itraconazole product labeling specifically contraindicates use with dofetilide while that of voriconazole and posaconazole contraindicate use with CYP3A4 substrates that prolong the QT interval (eg, dofetilide).</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Itraconazole, Ketoconazole (Systemic)*, Posaconazole, Voriconazole<br><b>Exceptions</b> Fluconazole, Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Coadministration of dofetilide (500 mcg twice daily) and ketoconazole (400 mg daily) for 7 days increased dofetilide AUC and Cmax by 41% and 53% in males, and by 69% and 97% in females, respectively.<sup>1</sup> Dofetilide product labeling suggests that ketoconazole inhibits renal secretion of dofetilide via inhibition of cation transporters. Data regarding the ability of other azole antifungals (eg, posaconazole, voriconazole, itraconazole) to inhibit renal cation transporters appears to be lacking. Dofetilide also undergoes limited hepatic metabolism via CYP3A4 and its product labeling recommends caution with concomitant use of CYP3A4 inhibitors such as azole antifungals. Itraconazole product labeling however, specifically contraindicates use with dofetilide.<sup>2</sup> Posaconazole and voriconazole product labelings contraindicate use with CYP3A4 substrates that prolong the QT interval (eg, dofetilide).<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Labs; Februay 2011.</p>\n<p>2. Sporanox (itraconazole) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; March 2009.</p>\n<p>3. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co. Inc.; September 2010.</p>\n<p>4. VFEND (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3456":"<p><b>Title</b> Didanosine / Stavudine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stavudine may enhance the adverse/toxic effect of Didanosine. The risk of lactic acidosis (possibly fatal), hepatomegaly, and pancreatitis may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of stavudine and didanosine. This combination is listed as contraindicated in the stavudine prescribing information.</p> \n<p><b>Discussion</b> The stavudine prescribing information states that fatal lactic acidosis, hepatomegaly with steatosis, fatal and nonfatal pancreatitis, and peripheral neuropathy have occurred when stavudine was combined with didanosine.<sup>1</sup> This combination is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zerit (stavudine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3458":"<p><b>Title</b> Indinavir / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Grapefruit Juice does not appear to affect serum concentration of Indinavir. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concomitant single doses of indinavir (800 mg) and grapefruit juice (180 mL double strength) delayed peak serum indinavir concentrations by 0.44 hours (from 1.12-1.56) in normal subjects.<sup>1</sup> Grapefruit juice did not alter the magnitude of the peak serum concentration nor the AUC of indinavir. An increased gastric pH was observed with grapefruit administration (changed from 1.5-3.3) This may be the reason for the observed delay in absorption. No clinical effects are expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shelton MJ, Wynn HE, Hewitt RG, et al, “Effects of Grapefruit Juice on Pharmacokinetic Exposure to Indinavir in HIV-positive Subjects,” <i>J Clin Pharmacol</i>, 2001, 41(4):435-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11304900\">[PubMed 11304900]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3460":"<p><b>Title</b> OLANZapine / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of OLANZapine. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased olanzapine effects/toxicities if combined with fluvoxamine. Consider reducing the dose of olanzapine or using a noninteracting SSRI instead of fluvoxamine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the olanzapine prescribing information, fluvoxamine increased the olanzapine AUC 54% in female nonsmokers and increased the olanzapine AUC 108% in male smokers.<sup>1</sup> A case report describes a patient treated with olanzapine (15 mg/day) who experienced increased serum olanzapine concentrations (120 mcg/L), mydriasis, tremor (hands), and rigid movement following several months of concomitant therapy with fluvoxamine (150 mg/day).<sup>2</sup> Symptoms resolved and the olanzapine serum concentration decreased (38 mcg/L) following olanzapine dosage decreases to 5 mg/day. Eventually the fluvoxamine was discontinued, and replaced with paroxetine without incident.<sup>2</sup> In an observational study, the olanzapine serum concentration/daily dose ratio was increased 2.3-fold in 10 patients receiving olanzapine plus fluvoxamine compared to 134 patients not receiving fluvoxamine.<sup>3</sup> Additionally, one report describes an attempt to take advantage of this interaction in order to reduce olanazapine dose requirements.<sup>4</sup> In this report a 26% decrease in olanzapine dosage with codministration of fluvoxamine (25 mg daily) resulted in negligible changes in serum olanzapine concentrations.<sup>4</sup><br><br>The mechanism of this interaction is likely due to fluvoxamine-mediated inhibition of CYP1A2, an enzyme responsible for olanzapine metabolism. Other SSRIs, due to their lack of effect on CYP1A2, would not be expected to interact with olanzapine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly LLC USA; February 2017.</p>\n<p>2. de Jong J, Hoogenboom B, van Troostwijk LD, de Haan L. Interaction of olanzapine with fluvoxamine. <i>Psychopharmacology (Berl)</i>. 2001;155(2):219-220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11401013\">[PubMed 11401013]</a></p>\n<p>3. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 2001;23(4):410-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477325\">[PubMed 11477325]</a></p>\n<p>4. Albers LJ, Ozdemir V, Marder SR, et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. <i>J Clin Psychopharmacol</i>. 2005;25(2):170-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15738749\">[PubMed 15738749]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3462":"<p><b>Title</b> Warfarin / ROPINIRole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> ROPINIRole may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Onset</b> Delayed (Sequence Important) <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased INR or warfarin effects if ropinirole is initiated or the dose increased, and decreased INR or warfarin effects if ropinirole is discontinued or the dose decreased.</p> \n<p><b>Discussion</b> A single case report describes a 63-year-old man, stable on warfarin (4 mg once daily for 2 years), who was started on ropinirole (0.25 mg 3 times daily).<sup>1</sup> Nine days later his INR increased to 4.6 and a reduced dose of warfarin (3 mg once daily) was needed to return his INR values to the therapeutic range. Upon discontinuation of the ropinirole (due to adverse gastrointestinal effects) his INR fell to subtherapeutic values and his warfarin dose was increased back to 4 mg once daily.<sup>1</sup> <br><br>The mechanism for this apparent interaction is unknown, but the authors of this case report propose that ropinirole inhibition of (or competition for) CYP1A2 (an enzyme partially responsible for R-warfarin metabolism) or competition for protein binding sites resulting in increased concentrations of unbound warfarin may play a role.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bair JD, Oppelt TF. Warfarin and ropinirole interaction. <i>Ann Pharmacother</i>. 2001;35(10):1202-1204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11675845\">[PubMed 11675845]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3463":"<p><b>Title</b> Lithium / Angiotensin II Receptor Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of lithium if an angiotensin II antagonist is initiated/dose increased, or decreased effects if an angiotensin II antagonist is discontinued/dose decreased. Lithium dosage reductions will likely be needed following the addition of an angiotensin II antagonist. The effects may take several weeks to manifest.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan*, Eprosartan, Fimasartan, Irbesartan, Losartan*, Olmesartan, Telmisartan, Valsartan*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A lithium-stable patient (900 mg/day) developed lithium toxicity (increased serum lithium concentrations, agitation, ataxia, confusion) within 7 weeks of initiating candesartan (16 mg/day).<sup>1</sup> Her serum lithium concentration increased approximately 4.5-fold. Other similar reports of lithium toxicity and up to 3-fold increases in serum lithium concentrations (within 1-3 weeks of angiotensin II receptor blocker initiation) have been reported with losartan,<sup>2</sup> valsartan,<sup>3,4</sup> and irbesartan.<sup>5</sup> The angiotensin II receptor blockers apparently reduce the renal elimination of lithium. A precise mechanism is unclear. The magnitude of the effects warrants caution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zwanzger P, Marcuse A, Boerner RJ, et al, “Lithium Intoxication After Administration of AT1 Blockers,” <i>J Clin Psychiatry</i>, 2001, 62(3):208-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11305712\">[PubMed 11305712]</a></p>\n<p>2. Blanche P, Raynaud E, Kerob D, et al, “Lithium Intoxication in an Elderly Patient After Combined Treatment With Losartan,” <i>Eur J Clin Pharmacol</i>, 1997, 52(6):501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9342587\">[PubMed 9342587]</a></p>\n<p>3. Leung M and Remick RA, “Potential Drug Interaction Between Lithium and Valsartan,” <i>J Clin Psychopharmacol</i>, 2000, 20(3):392-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10831034\">[PubMed 10831034]</a></p>\n<p>4. Su YP, Chang CJ, Hwang TJ, “Lithium Intoxication After Valsartan Treatment,” <i>Psychiatry Clin Neurosci</i>, 2007, 61:204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17362443\">[PubMed 17362443]</a></p>\n<p>5. Spinewine A, Schoevaerdts D, Swine C, et al, “Drug-Induced Lithium Intoxication: A Case Report,” <i>J Am Geriatr Soc</i>, 2005, 53(2):360-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15673374\">[PubMed 15673374]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3464":"<p><b>Title</b> Ziprasidone / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Ziprasidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced therapeutic effects of ziprasidone if carbamazepine is initiated/dose increased, or toxic effects if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The mean ziprasidone AUC was 36% lower in 25 healthy subjects following a 24-day course of carbamazepine (100 mg/day x 2 days, 100 mg twice/day x 2 days, 200 mg twice/day x 20 days).<sup>1,2</sup> Though this study was not designed to evaluate the impact of this on ziprasodone pharmacodynamics, some patients may experience reduced clinical effects. It is also important to note that only a modest carbamazepine dose was studied, suggesting that larger carbamazepine doses may be associated with greater changes in ziprasodone concentrations.<sup>2</sup> The likely mechanism of this interaction is carbamazepine induction of CYP3A4, leading to increased metabolism of ziprasidone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Miceli JJ, Anziano RJ, Robarge L, et al, “The Effect of Carbamazepine on the Steady-State Pharmacokinetics of Ziprasidone in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 2000, 49(Suppl 1):65S-70S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10771457\">[PubMed 10771457]</a></p>\n<p>2. Prescribing information. Geodon (ziprasidone). New York, NY: Pfizer Inc, 12/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3465":"<p><b>Title</b> Fexofenadine / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Fexofenadine. RifAMPin may increase the serum concentration of Fexofenadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased fexofenadine effects if administered simultaneously with rifampin. Monitor for decreased fexofenadine effects if given around 8 h after rifampin, particularly when rifampin has already been given for several days. The impact of other dosing schedules on fexofenadine exposure has not been studied.</p> \n<p><b>Discussion</b> In clinical studies of healthy volunteers, the AUC of a single oral dose of fexofenadine (60 mg) was altered in an apparently dose-time-dependent manner by rifampin: fexofenadine AUC was increased by roughly 3.6 fold when given simultaneously with a single 600 mg rifampin dose;<sup>1</sup> fexofenadine AUC was increased by roughly 2.4 fold when given simultaneously with the sixth daily 600 mg dose of rifampin;<sup>1</sup> and fexofenadine AUC was decreased 47-63% when given following the sixth daily 600 mg dose of rifampin.<sup>2</sup> <br><br>The mechanisms of interaction between these agents have not been fully characterized. Rifampin induction of CYP3A4 mediated fexofenadine metabolism and P-glycoprotein mediated fexofenadine efflux could decrease fexofenadine exposure, particularly after several days of rifampin treatment. However, a second and likely more transient mechanism such as rifampin inhibition of P-glycoprotein mediated intestinal efflux or OATP1B3 mediated fexofenadine hepatic uptake appears to actually increase rather than decrease fexofenadine exposure when the two agents are given simultaneously.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kusuhara H, Miura M, Yasui-Furukori N, et al, “Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects,” <i>Drug Metab Dispos</i>, 2013, 41(1):206-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23115085\">[PubMed 23115085]</a></p>\n<p>2. Hamman MA, Bruce MA, Haehner-Daniels BD, et al, “The Effect of Rifampin Administration on the Disposition of Fexofenadine,” <i>Clin Pharmacol Ther</i>, 2001, 69(3):114-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11240975\">[PubMed 11240975]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3466":"<p><b>Title</b> Mexiletine / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased. Citalopram, escitalopram, and sertraline are expected to interact less (possibly causing no clinical problems at all) than the other SSRI. Consider avoiding the concomitant use of mexiletine with fluoxetine, fluvoxamine, or paroxetine.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine*, FluvoxaMINE*, PARoxetine*, Vilazodone, Vortioxetine<br><b>Exception</b> Sertraline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The mean AUC of oral mexiletine (200 mg single dose) was increased more than 50% in 6 normal subjects when administered following a 7-day course of fluvoxamine (50 mg twice daily).<sup>1</sup> No data regarding pharmacodynamic effects were reported. In vitro data predicts significant reductions in the in vivo clearance of mexiletine during concomitant use of fluoxetine and paroxetine.<sup>2</sup> Mexiletine is metabolized via CYP1A2 and CYP2D6 isoenzymes. Fluvoxamine is a potent CYP1A2 inhibitor, and thus would be expected to reduce mexiletine clearance. No other SSRI appears to possess appreciable CYP1A2 inhibiting potential; however, fluoxetine and paroxetine are potent inhibitors of CYP2D6, and therefore are expected to have a similar effect on mexiletine. Citalopram (escitalopram) is a moderate CYP2D6 inhibitor. Sertraline is weak CYP2D6 inhibitor, and would therefore be expected to have minimal effect on mexiletine pharmacokinetics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kusumoto M, Ueno K, Oda A, et al, “Effect of Fluvoxamine on the Pharmacokinetics of Mexiletine in Healthy Japanese Men,” <i>Clin Pharmacol Ther</i>, 2001, 69(3):104-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11240973\">[PubMed 11240973]</a></p>\n<p>2. Hara Y, Nakajima M, Miyamoto KI, et al, “Inhibitory Effects of Psychotropic Drugs on Mexiletine Metabolism in Human Liver Microsomes: Prediction of in vivo Drug Interactions,” <i>Xenobiotica</i>, 2005, 35(6):549-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192107\">[PubMed 16192107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3467":"<p><b>Title</b> Beta-Blockers / Aminoquinolines (Antimalarial)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of beta-blockers if an aminoquinoline antimalarial agent is initiated/dose increased, or decreased effects if such an antimalarial is discontinued/dose decreased. Beta-blockers eliminated primarily by renal mechanisms (e.g., atenolol, nadolol, sotalol) are less likely to be involved in this interaction.</p>\n<div>\n <p><b>Aminoquinolines (Antimalarial) Interacting Members</b> Chloroquine, Hydroxychloroquine*, Primaquine</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Atenolol, Carteolol (Ophthalmic), Levobunolol, Metipranolol, Nadolol, Sotalol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The average AUC of metoprolol (100 mg single dose) was increased 65% when administered following a 7-day course of hydroxychloroquine in a study of 7 healthy volunteers.<sup>1</sup> Though this study was not designed to fully evaluate the clinical significance of this interaction, the potential for increased beta-blocker activity and greater adverse effects (including a loss of cardioselectivity for those beta1-selective agents) exists.<br><br>The mechanism of this interaction is likely inhibition of the CYP2D6-mediated metabolism of metoprolol by hydroxychloroquine. In vivo studies have shown other aminoquinolines, such as chloroquine and amodiaquine, are also capable of inhibiting CYP2D6.<sup>2,3,4</sup> Other beta-blockers that are at least partially dependent on CYP2D6 for their metabolism are likely similarly vulnerable to this potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. <i>Br J Clin Pharmacol</i>. 2000;49(6):549-554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10848718\">[PubMed 10848718]</a></p>\n<p>2. Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. <i>Eur J Clin Pharmacol</i>. 2006;62(7):539-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16783563\">[PubMed 16783563]</a></p>\n<p>3. Simooya OO, Sijumbil G, Lennard MS, Tucker GT. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. <i>Br J Clin Pharmacol</i>. 1998;45(3):315-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10896408\">[PubMed 10896408]</a></p>\n<p>4. Adedoyin A, Frye RF, Mauro K, Branch RA. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. <i>Br J Clin Pharmacol</i>. 1998;46(3):215-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9764961\">[PubMed 9764961]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3469":"<p><b>Title</b> Retinoic Acid Derivatives / Tetracyclines</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), ISOtretinoin (Systemic), Tretinoin (Systemic)*<br><b>Exceptions</b> Adapalene, Bexarotene (Topical), Tretinoin (Topical)</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline*, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe the development of pseudotumor cerebri (also known as intracranial hypertension; characterized by dizziness, diplopia, and headache) in patients receiving retinoic acid derivatives (eg, isotretinoin, etretinate), a significant number of which were also receiving a tetracycline antibiotic.<sup>1,2,3</sup> The manufacturers of several retinoid products either contraindicate or caution against the combination of systemic retinoids and tetracycline derivatives.<sup>1,4</sup><br><br>The mechanism of this interaction is unclear, but it is suspected that the interaction results from each agent's ability to independently increase intracranial pressure. Of the systemic retinoids, reports of pseudotumor cerebri have been described for isotretinoin, tretinoin, etretinate, and acitretin (though not all have reports implicating the retinoid-tetracycline combination).<sup>1,2,3,4</sup> As detailed in a review of pseudotumor cerebri, of the tetracycline derivatives, tetracycline, minocycline, and doxycycline have all been associated with pseudotumor cerebri, with doxycycline possibly having the lowest risk of the three.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Accutane [package insert]. Nutley, NJ: Roche Pharmaceuticals, 2000.</p>\n<p>2. Viraben R, Matthieu C, and Fonton B, “Benign Intracranial Hypertension During Etretinate Therapy for Mycosis Fungoides,” <i>J Am Acad Dermatol</i>, 1985, 13:515-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4056125\">[PubMed 4056125]</a></p>\n<p>3. Fraunfelder FW, Fraunfelder FT, “Evidence for a Probable Causal Relationship Between Tretinoin, Acitretin, and Etretinate and Intracranial Hypertension,” <i>J Neuro-Ophthalmol</i>, 24(3):214-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15348987\">[PubMed 15348987]</a></p>\n<p>4. Soriatane [package insert]. Palo Alto, CA: Connetics Corporation, 2004.</p>\n<p>5. Starling J, Koo J, “Evidence Based or Theoretical Concern? Pseudotumor Cerebri and Depression as Acitretin Side Effects,” <i>J Drugs Dermatol</i>, 2005, 4(6):690-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16302554\">[PubMed 16302554]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3470":"<p><b>Title</b> Lithium / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased lithium concentrations if a carbonic anhydrase inhibitor is initiated/dose increased or increased concentrations if a carbonic anhydrase inhibitor is stopped/dose decreased.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE*, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One small study (N=6) showed 31% average increases in renal lithium excretion following a single oral dose of acetazolamide 500 - 750 mg.<sup>1</sup> In two later studies, lithium excretion increased by approximately 60% following a single intravenous dose of acetazolamide 10 mg/kg administered over 15 minutes (N=14)<sup>2</sup> and by approximately 43% and 133% in salt-depleted and salt-replete subjects, respectively, following a single oral dose of acetazolamide 500 mg (N=10).<sup>3</sup><br> <br>The exact mechanism by which carbonic anhydrase inhibitors may increase lithium excretion is unknown. Increases in renal lithium excretion could decrease circulating lithium concentrations and possibly promote therapeutic failure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomson K and Schou M, “Renal Lithium Excretion in Man,” <i>Am J Physiol</i>, 1968, 215:823.</p>\n<p>2. Colussi G, Rombola G, Surian M, et al, “Lithium Clearance in Humans: Effects of Acute Administration of Acetazolamide and Furosemide,” <i>Kidney Int Suppl</i>, 1990, 28:S63-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2325337\">[PubMed 2325337]</a></p>\n<p>3. Atherton JC, Doyle A, Gee A, et al, “Lithium Clearance: Modification by the Loop of Henle in Man,” <i>J Physiol</i>, 1991, 437:377-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1890640\">[PubMed 1890640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3471":"<p><b>Title</b> Phenytoin / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of phenytoin if amiodarone is initiated/dose increased, and decreased serum concentrations/effects if amiodarone is discontinued/dose decreased. Monitor for decreased amiodarone serum concentrations/effects if phenytoin is initiated/dose increased, and increased serum concentrations/effects if phenytoin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Serum phenytoin concentrations have been reported to increase two to fourfold within a few weeks of initiating amiodarone therapy (400-1200 mg/day) with resultant phenytoin toxicity.<sup>1,2,3</sup> Pharmacokinetic studies in normal subjects showed that amiodarone (200 mg/day) for 3-6 weeks resulted in up to 40% increases in serum phenytoin concentrations.<sup>4,5</sup> Amiodarone likely inhibits the CYP2C9 metabolism of phenytoin.<br><br>In addition to the effects on phenytoin, serum amiodarone concentrations have been noted to decrease during concomitant therapy. Phenytoin administration (3-4 mg/kg/day) for 2 weeks caused serum amiodarone concentrations to decrease by 33% to 49% below predicted values.<sup>6,7</sup> This is likely due to phenytoin induction of CYP isoenzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McGovern B, Geer VR, LaRaia PJ, et al, “Possible Interaction Between Amiodarone and Phenytoin,” <i>Ann Intern Med</i>, 1984, 101:650-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6486598\">[PubMed 6486598]</a></p>\n<p>2. Shackleford EJ and Watson FT, “Amiodarone-Phenytoin Interaction,” <i>Drug Intell Clin Pharm</i>, 1987, 21:921. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3678068\">[PubMed 3678068]</a></p>\n<p>3. Ahmad S, “Amiodarone and Phenytoin Interaction,” <i>J Am Geriatr Soc</i>, 1995, 43:1449-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7490410\">[PubMed 7490410]</a></p>\n<p>4. Nolan PE, Marcus FI, Hoyer GL, et al, “Pharmacokinetic Interaction Between Amiodarone and Phenytoin,” <i>J Am Coll Cardiol</i>, 1987, 9(2 Suppl A):47A.</p>\n<p>5. Nolan PE, Erstad BL, Hoyer GL, et al, “Steady-State Interaction Between Amiodarone and Phenytoin in Normal Subjects,” <i>Am J Cardiol</i>, 1990, 65:1252-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2337037\">[PubMed 2337037]</a></p>\n<p>6. Nolan PE, Marcus FI, Karol MD, et al, “Evidence for an Effect of Phenytoin on the Pharmacokinetics of Amiodarone,” <i>Pharmacotherapy</i>, 1998, 8:121.</p>\n<p>7. Nolan PE, Marcus FI, Karol MD, et al, “Effect of Phenytoin on the Clinical Pharmacokinetics of Amiodarone,” <i>J Clin Pharmacol</i>, 1990, 30:1112-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273084\">[PubMed 2273084]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3473":"<p><b>Title</b> DOXOrubicin (Conventional) / Taxane Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Taxane Derivatives may decrease the metabolism of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using docetaxel instead of paclitaxel as a way to avoid this potential interaction. If doxorubicin and a taxane derivative (especially paclitaxel) are used concomitantly, diligently monitor for the development of doxorubicin toxicity (e.g., congestive heart failure). Administer doxorubicin prior to paclitaxel when used concomitantly.</p>\n<div>\n <p><b>Taxane Derivatives Interacting Members</b> Cabazitaxel, PACLitaxel (Conventional)*, PACLitaxel (Protein Bound)<br><b>Exception</b> DOCEtaxel</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Paclitaxel administration has been shown to decrease the clearance of doxorubicin (and doxorubicinol) to a clinically significant extent, resulting in increased toxicity (eg, congestive heart failure).<sup>1</sup> The mechanism of this interaction is unclear, but may be related to competition for metabolic isoenzymes (eg, CYP3A4) or transport proteins (eg, p-glycoprotein). Docetaxel does not appear to share this same interaction potential, and thus may be a better therapy choice in some clinical situations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Holmes FA and Rowinsky EK, “Pharmacokinetic Profiles of Doxorubicin in Combination With Taxanes,” <i>Semin Oncol</i>, 2001, 28(4 Suppl 12):8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11552225\">[PubMed 11552225]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3474":"<p><b>Title</b> Vitamin K Antagonists / SulfaSALAzine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SulfaSALAzine may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased INR/warfarin effects if sulfasalazine is initiated/dose increased, and increased INR/warfarin effects if sulfasalazine is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A warfarin-stable patient (approximately 30 mg/week) experienced a decreased INR and DVT following the discontinuation of mesalamine and initiation of sulfasalazine.<sup>1</sup> She was restabilized on a warfarin dosage of 75 mg/week. Subsequent discontinuation of sulfasalazine and reinitiation of mesalamine resulted in an increased INR (eventually stabilized on approximately 45 mg/week). Sulfonamides are known to enhance warfarin effects. The reason for the decreased effects caused by sulfasalazine are not understood. Mesalamine, a chemically similar product, did not appear to significantly affect warfarin activity. It is unclear whether sulfasalazine affected the disposition of warfarin, or possibly induced some form of warfarin resistance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Teefy AM, Martin JE, and Kovacs MJ, “Warfarin Resistance Due to Sulfasalazine,” <i>Ann Pharmacother</i>, 2000, 34(11):1265-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11098339\">[PubMed 11098339]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3475":"<p><b>Title</b> Haloperidol / ChlorproMAZINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> ChlorproMAZINE may enhance the QTc-prolonging effect of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE. ChlorproMAZINE may increase the serum concentration of Haloperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to combined treatment with chlorpromazine and haloperidol. Increased concentrations and QTc interval prolonging effects of both agents could result with the combination. If concomitant treatment cannot be avoided, monitor for signs and symptoms of prolonged QTc interval (e.g. arrhythmias).</p> \n<p><b>Discussion</b> Coadministration of chlorpromazine increased dose-adjusted 12 hour post-dose concentrations of haloperidol by an average of 28.5% (standard deviation 83.3%) in a group of 43 schizophrenic male patients.<sup>1</sup> Doses of both agents varied by patient. Individuals with CYP2D6 *1/*1 genotype had a trend toward greater increases in haloperidol concentration with chlorpromazine compared to individuals carrying 1 or more copies of *5 or *10 haplotypes. <br><br>The likely mechanism of the observed interaction is chlorpromazine inhibition of haloperidol metabolism via CYP2D6. Haloperidol could theoretically increase chlorpromazine concentrations via CYP2D6 inhibition as well, although this was not studied. Increased exposure to and toxic effects of both drugs could result. Of particular concern is the possibility for enhanced QTc interval prolongation, an effect associated with both drugs independent of the other. Although CYP2D6 phenotype may be predictive of the magnitude of interaction between these agents, caution should be employed regardless of CYP2D6 activity. Patients with low CYP2D6 function would be at risk of increased exposure to the drugs independent of the presence of CYP2D6 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Suzuki Y, Someya T, Shimoda K, et al, “Importance of the Cytochrome P450 2D6 Genotype for the Drug Metabolic Interaction between Chlorpromazine and Haloperidol,” <i>Ther Drug Monit</i>, 2001, 23(4):363-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477317\">[PubMed 11477317]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3477":"<p><b>Title</b> Vecuronium / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Vecuronium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced magnitude and duration of vecuronium effects in patients receiving carbamazepine.</p> \n<p><b>Discussion</b> A case report and several clinical studies have shown shortened neuromuscular blockade recovery time, increased vecuronium clearance, and increased vecuronium dose requirements in patients receiving carbamazepine.<sup>1,2,3,4</sup> In one study, the elimination half-life of vecuronium (0.15 mg/kg IV bolus) was decreased by approximately 60% in 10 epileptic children receiving carbamazepine compared with 10 nonepileptic children (matched for age and weight) who were not receiving carbamazepine.<sup>2</sup> In adults, clearance of vecuronium was increased approximately 2.4 fold in patients receiving carbamazepine.<sup>3</sup> Another study demonstrated shortened time to recovery from neuromuscular blockade in patients taking carbamazepine, phenytoin, or phenobarbitone.<sup>5</sup> <br><br>The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norman J, “Resistance to Vecuronium,” <i>Anaesthesia</i>, 1993, 48(12):1068-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7904430\">[PubMed 7904430]</a></p>\n<p>2. Soriano SG, Sullivan LJ, Venkatakrishnan K, et al, “Pharmacokinetics and Pharmacodynamics of Vecuronium in Children Receiving Phenytoin or Carbamazepine for Chronic Anticonvulsant Therapy,” <i>Br J Anaesth</i>, 2001, 86(2):223-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11573664\">[PubMed 11573664]</a></p>\n<p>3. Alloul K, Whalley DG, Shutway F, et al, “Pharmacokinetic Origin of Carbamazepine-Induced Resistance to Vecuronium Neuromuscular Blockade in Anesthetized Patients,” <i>Anesthesiology</i>, 1996, 84(2):330-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8602663\">[PubMed 8602663]</a></p>\n<p>4. Whalley DG and Ebrahim Z, “Influence of Carbamazepine on the Dose-Response Relationship of Vecuronium,” <i>Br J Anaesth</i>, 1994, 72(1):125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7906533\">[PubMed 7906533]</a></p>\n<p>5. Hans P, Brichant JF, Pieron F, et al, “Elevated Plasma Alpha 1-Acid Glycoprotein Levels: Lack of Connection to Resistance to Vecuronium Blockade Induced by Anticonvulsant Therapy,” <i>J Neurosurg Anesthesiol</i>, 1997, 9(1):3-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9016432\">[PubMed 9016432]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3478":"<p><b>Title</b> Phosphate Supplements / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phosphate supplements are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Phosphate Supplements. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent administration of aluminum-, magnesium-, or calcium-containing antacids with an oral phosphate supplement should be avoided. Separation of the oral administration of these products may minimize the potential for a significant interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Phosphate Supplements Interacting Members</b> Potassium Phosphate, Sodium Phosphates<br><b>Exception</b> Sodium Glycerophosphate Pentahydrate</p>\n</div> \n<p><b>Discussion</b> Polyvalent cations (following oral administration) may bind to oral phosphate in the gastrointestinal tract, reducing its bioavailability. The therapeutic effect of the phosphate would be reduced. Concurrent administration of aluminum-, magnesium-, or calcium-containing antacids with an oral phosphate supplement should be avoided.<sup>1,2,3</sup> Separation of the oral administration of these products may minimize the potential for a significant interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phospha 250 Neutral (sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic and sodium phosphate, monobasic, monohydrate) [prescribing information]. Allendale, NJ: Rising Pharmaceuticals, Inc.; June 2012.</p>\n<p>2. K-Phos No. 2 (potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</p>\n<p>3. K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3479":"<p><b>Title</b> Phosphate Supplements / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phosphate supplements and calcium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the absorption of Phosphate Supplements. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent ingestion of calcium salts may significantly decrease the absorption of phosphate. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p><b>Phosphate Supplements Interacting Members</b> Potassium Phosphate, Sodium Phosphates<br><b>Exception</b> Sodium Glycerophosphate Pentahydrate</p>\n</div> \n<p><b>Discussion</b> Polyvalent cations (following oral administration) can bind to oral phosphate in the gastrointestinal tract, reducing its bioavailability.<sup>1,2</sup> A study examining the impact of calcium intake on the absorption of dietary phosphate estimated that phosphate absorption was reduced by 0.166 g for each 0.5 g increase in calcium intake.<sup>1</sup> Of note, a study in 6 healthy volunteers demonstrated considerable variability in the phosphate-binding capacity of different calcium and aluminum preparations,<sup>2</sup> suggesting that the magnitude and significance of this interaction will likely vary according to the specific calcium salt and formulation being used.<br><br>Considering that the mechanism of this interaction is likely calcium binding to phosphate, resulting in the formation of a non-absorbable complex, separation of calcium and phosphate doses may be able to avoid or minimize this interaction. It is also important to note that this ability of calcium to bind phosphate in the gut is used to intentionally reduce phosphate absorption in certain patients, such as those with severe renal dysfunction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. <i>J Am Coll Nutr</i>. 2002;21(3):239-244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12074251\">[PubMed 12074251]</a></p>\n<p>2. Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. <i>Int J Artif Organs</i>. 1998;21(1):19-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9554821\">[PubMed 9554821]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3480":"<p><b>Title</b> Phosphate Supplements / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phosphate supplements and magnesium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Phosphate Supplements. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent ingestion of oral magnesium salts may significantly decrease the absorption of oral phosphate. Administering oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible may be able to minimize the significance of the interaction.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n <p><b>Phosphate Supplements Interacting Members</b> Potassium Phosphate, Sodium Phosphates<br><b>Exception</b> Sodium Glycerophosphate Pentahydrate</p>\n</div> \n<p><b>Discussion</b> Divalent cations (following oral administration) can bind to oral phosphate in the gastrointestinal tract, reducing its bioavailability.<sup>1</sup> The therapeutic effect of the phosphate may be reduced.<sup>1</sup> Doses should be separated to avoid this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3481":"<p><b>Title</b> Phosphate Supplements / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phosphate supplements and iron salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the absorption of Phosphate Supplements. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent ingestion of iron salts may significantly decrease the absorption of oral phosphate. Administering oral phosphate supplements as far apart from the administration of an oral iron salt as possible may be able to minimize the significance of the interaction.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p><b>Phosphate Supplements Interacting Members</b> Potassium Phosphate, Sodium Phosphates<br><b>Exception</b> Sodium Glycerophosphate Pentahydrate</p>\n</div> \n<p><b>Discussion</b> Divalent cations (following oral administration) can bind to oral phosphate in the gastrointestinal tract, reducing its bioavailability.<sup>1</sup> The therapeutic effect of the phosphate may be reduced.<sup>1</sup> Doses should be separated to avoid this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. K-Phos Original (potassium acid phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3482":"<p><b>Title</b> Phosphate Supplements / Sucralfate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phosphate supplements are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the absorption of Phosphate Supplements. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent ingestion of sucralfate may significantly decrease the absorption of oral phosphates. Administering oral phosphate supplements at least 1 hour before or 2 hours after administration of sucralfate may be able to minimize the significance of the interaction. However, considering the potentially prolonged presence of at least some sucralfate in the gastrointestinal tract following administration, it is unclear how effective dose-separation will be at minimizing this interaction.</p>\n<div>\n <p><b>Phosphate Supplements Interacting Members</b> Potassium Phosphate, Sodium Phosphates<br><b>Exception</b> Sodium Glycerophosphate Pentahydrate</p>\n</div> \n<p><b>Discussion</b> Polyvalent cations (following oral administration) such as aluminum, which is a component of sucralfate, can bind to oral phosphate in the gastrointestinal tract, reducing its bioavailability.<sup>1,2,3,4</sup> Studies examining the impact of sucralfate on phosphate concentrations have demonstrated that sucralfate is generally similar to aluminum hydroxide in its phosphate-binding capability.<sup>1,2</sup> Though specific studies of sucralfate with phosphate supplements are not available, published case reports describe patients who experienced clinical hypophosphatemia associated with sucralfate use,<sup>3,4</sup> strongly suggesting that a sucralfate-phosphate supplement interaction do exist.<br><br>Considering that the mechanism of this interaction is likely sucralfate (i.e., aluminum) binding to phosphate, resulting in the formation of a non-absorbable complex, separation of sucralfate and phosphate doses may be able to minimize this interaction. However, considering the potentially prolonged presence of at least some sucralfate in the gastrointestinal tract following administration, it is unclear how effect dose-separation will be at minimizing this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Leung AC, Henderson IS, Halls DJ, et al, “Aluminium Hydroxide Versus Sucralfate as a Phosphate Binder in Uraemia,” <i>Br Med J (Clin Res Ed)</i>, 1983, 286(6375):1379-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6404468\">[PubMed 6404468]</a></p>\n<p>2. Roxe DM, Mistovich M, Barch DH, “Phosphate-Binding Effects of Sucralfate in Patients with Chronic Renal Failure,” <i>Am J Kidney Dis</i>, 1989, 13(3):194-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2919600\">[PubMed 2919600]</a></p>\n<p>3. Chines A, Pacifici R, “Antacid and Sucralfate-Induced Hypophosphatemic Osteomalacia: A Case Report and Review of the Literature,” <i>Calcif Tissue Int</i>, 1990, 47(5):291-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2257522\">[PubMed 2257522]</a></p>\n<p>4. Miller SJ, Simpson J, “Medication-Nutrient interactions: Hypophosphatemia Associated with Sucralfate in the Intensive Care Unit,” <i>Nutr Clin Pract</i>, 1991, 6(5):199-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1775116\">[PubMed 1775116]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3484":"<p><b>Title</b> Herbs (Anticoagulant/Antiplatelet Properties) / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of other Herbs (Anticoagulant/Antiplatelet Properties). Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (e.g. bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3485":"<p><b>Title</b> Agents with Antiplatelet Properties / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3486":"<p><b>Title</b> Anticoagulants / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3487":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3488":"<p><b>Title</b> Salicylates / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of Salicylates. Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3489":"<p><b>Title</b> Thrombolytic Agents / Herbs (Anticoagulant/Antiplatelet Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Herbs (Anticoagulant/Antiplatelet Properties) may enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of herbs possessing anticoagulation/antiplatelet properties with other herbs or drugs possessing similar properties should be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed. For patients scheduled for surgical, dental, or other invasive procedures, anticoagulant/antiplatelet herbs should be discontinued 2 weeks prior to the scheduled procedure.</p>\n<div>\n <p><b>Herbs (Anticoagulant/Antiplatelet Properties) Interacting Members</b> Alfalfa, Anise, Bilberry, Bladderwrack, Bromelain, Cat's Claw, Celery, Chamomile, Coleus, Cordyceps, Dong Quai, Evening Primrose, Fenugreek, Feverfew, Garlic, Ginger, Ginkgo Biloba, Ginseng (American), Ginseng (Panax), Ginseng (Siberian), Grape Seed, Green Tea, Guggul, Horse Chestnuts, Horseradish, Licorice, Prickly Ash, Red Clover, Reishi, SAMe (S-adenosylmethionine), Sweet Clover, Taurine, Turmeric, White Willow</p>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> Many herb products possess the ability to cause bleeding (inhibit clotting/coagulation or primary hemostasis) by one of several mechanisms (e.g., herb contains a coumarin-like constituent or one that is able to inhibit the production/function of platelets).<sup>1,2,3,4</sup> The concomitant use of such herbs with other herbs or drugs possessing a similar pharmacologic potential may increase the risk of bleeding. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mousa SA, “Antithrombotic Effects of Naturally Derived Products on Cagulation and Platelet Function,” <i>Methods Mol Biol</i>, 2010, 663:229-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20617421\">[PubMed 20617421]</a></p>\n<p>2. Stanger MJ, Thompson LA, Young AJ, et al, “Anticoagulant Activity of Select Dietary Supplements,” <i>Nutr Rev</i>, 2012, 70(2):107-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22300597\">[PubMed 22300597]</a></p>\n<p>3. Spolarich AE, Andrews L, “An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications,” <i>J Dent Hyg</i>, 2007, 81(3):67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17908423\">[PubMed 17908423]</a></p>\n<p>4. Ulbricht C, Chao W, Costa D, et al, “Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration,” <i>Curr Drug Metab</i>, 2008, 9(10):1063-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19075623\">[PubMed 19075623]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3490":"<p><b>Title</b> Agents with Antiplatelet Properties / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK labeling lists the use of intravenous diclofenac in combination with other nonsteroidal anti-inflammatory agents as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the antiplatelet effect of other Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring diligence for signs and symptoms of bleeding if multiple drugs with antiplatelet properties are used concomitantly.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Each of the agents listed possess the potential to cause bleeding. Their combined use is expected to further increase that potential, and such potential for increased antiplatelet effects/bleeding risks are often specifically noted in product labeling.<sup>1,2,3</sup><br><br>Data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial demonstrated that the addition of clopidogrel to an aspirin-containing regimen in patients being treated for acute coronary syndromes has beneficial effects, reducing the risk of the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or stroke.<sup>4,5</sup> The risk of major bleeding, however, was also increased. Ticlopidine use with aspirin may likewise result in enhanced effects on platelet aggregation.<sup>6</sup> According to anagrelide US prescribing information, two clinical studies revealed greater inhibition of platelet aggregation (ex vivo) with the combination of anagrelide and aspirin compared to aspirin alone.<sup>7</sup> Preliminary data from an observational study also suggest that major hemorrhagic events are more common with anagrelide than with another unspecified cytoreductive treatment, and in most cases these events occur in patients receiving anti-aggregatory treatment (primarily aspirin). <br><br>Multiple case-control and retrospective cohort studies have reported statistically significant increases in gastrointestinal bleeding with concurrent use of serotonin reuptake inhibitors with nonsteroidal anti-inflammatory drugs (NSAIDs).<sup>8,9,10,11,12,13,14,15,16</sup> Some studies evaluating the risk of intracranial bleeding with combination therapy have found a marginally significant increase in risk, while others have reported a nonsignificant risk compared to use of NSAIDs alone.<sup>18,19,20,21</sup><br><br>A case-control study of 319 patients hospitalized for acute lower GI bleeding and 3,358 patients without bleeding on colonoscopy found that: NSAID use was associated with a 2.3 fold greater odds of bleeding; NSAID use in combination with low dose aspirin (81-100 mg/day) or other antiplatelet agents (cilostazol, dipyridamole, sarpogrelate hydrochloride, ethyl icosapentate, dilazep, limaprost, or beraprost) was associated with a 4.3 to 4.9 fold greater odds of bleeding; and the use of low-dose aspirin in combination with thienopyridines or other antiplatelet agents was associated with a 2.2 to 3.6 fold increased odds of bleeding, even though none of these agents/classes was independently associated with an increased odds of bleeding.<sup>22</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Plavix</i> (clopidogrel) [prescribing information]. New York, NY: Bristol-Myers Squibb; December 2013.</p>\n<p>2. <i>Prozac</i> (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; July 2013.</p>\n<p>3. <i>Reopro</i> (abciximab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2013.</p>\n<p>4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. <i>N Engl J Med</i>. 2001;345(7):494-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11519503\">[PubMed 11519503]</a></p>\n<p>5. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). <i>Lancet</i>. 1996;348:1329-1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8918275\">[PubMed 8918275]</a></p>\n<p>2. <i>Ticlid</i> (ticlopidine) [prescribing information]. Nutley, NJ: Roche Laboratories; April 2001.</p>\n<p>7. <i>Agrylin</i> (anagrelide) [prescribing information]. Wayne, PA: Shire US Inc; November 2011.</p>\n<p>8. de Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. <i> Br J Clin Pharmacol</i>. 2003;55(6):591-595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814454\">[PubMed 12814454]</a></p>\n<p>9. Dalton SO, Johansen C, Mellemjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. <i> Arch Intern Med</i>. 2003;163(1):59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>10. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. <i>BMJ</i>. 1999;319(7217):1106-1109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>11. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. <i>BMJ</i>. 2001;323(7314):655-658. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>12. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. <i>Aliment Pharmacol Ther</i>. 2006;23(7):937-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p>13. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? <i>Aliment Pharmacol Ther</i>. 2005;22(23):175-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16091054\">[PubMed 16091054]</a></p>\n<p>14. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19716436\">[PubMed 19716436]</a></p>\n<p>15. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18188866\">[PubMed 18188866]</a></p>\n<p>16. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. <i>Arch Gen Psychiatry</i>. 2008;65(7):795-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18606952\">[PubMed 18606952]</a></p>\n<p>17. Perahia DG, Bangs ME, Zhang Q, et al. The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. <i>Drug Healthc Patient Saf</i>. 2013;5:211-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24348072\">[PubMed 24348072]</a></p>\n<p>18. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. <i> Br J Clin Pharmacol</i>. 2000;50(1):43-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10886117\">[PubMed 10886117]</a></p>\n<p>19. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. <i>Stroke</i>. 2002;33(6):1465-1473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12052976\">[PubMed 12052976]</a></p>\n<p>20. Vidal X, Ibanez L, Vendrell L, Conforti A, Laporte JR; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. <i>Drug Saf</i>. 2008;31(2):159-168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18217791\">[PubMed 18217791]</a></p>\n<p>21. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19491861\">[PubMed 19491861]</a></p>\n<p>22. Nagata N, Niikura R, Aoki T, et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy [published online August 1, 2014]. <i>Gastrointest Endosc</i>. Doi:10.1016/j.gie.2014.06.039. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25088922\">[PubMed 25088922]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3491":"<p><b>Title</b> Anticoagulants / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK labeling lists the use of intravenous diclofenac in combination with anticoagulants (including low dose heparin) as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring diligence for signs and symptoms of bleeding if these agents are used concomitantly.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Each of these agents possess the potential to cause bleeding. Their combined use would seem to increase that potential. Product labeling will often note this potential problem.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reopro [package insert]. Indianapolis, IN: Eli Lilly and Company; 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3492":"<p><b>Title</b> Thrombolytic Agents / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Antiplatelet agents should be discontinued, and enough time should elapse for their effects to subside, before initiation of long-term streptokinase treatment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for signs and symptoms of bleeding if thrombolytic agents are to be used with other drugs that alter coagulation, inhibit platelet function, or are thrombolytic. Use of such combinations may further increase the potential for bleeding complications. Antiplatelet agents should be discontinued, and enough time should elapse for their effects to subside, before initiation of long-term streptokinase treatment.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> As thrombolytics are agents that interfere with normal clotting function, the use of thrombolytics with other agents that interfere with coagulation (e.g., antiplatelet agents) may further increase the risk for bleeding complications.<sup>1,2,3,4</sup> As a result of the potential for an increased risk of bleeding, careful monitoring for bleeding complications should accompany the use of any such combinations. This risk may persist for several days after discontinuation of the thrombolytic agent (but while the heparin, or similar agent, is continued).<sup>1,2,3</sup> The streptokinase Australian summary of product characteristics specifically recommends that antiplatelet agents should be discontinued, and enough time should elapse for their effects to subside, before initiation of long-term streptokinase treatment.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Retavase</i> (reteplase) [prescribing information]. Fremont, CA: PDL BioPharma, Inc.; November 2006.</p>\n<p>2. <i>TNKase</i> (tenecteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc.; January 2008.</p>\n<p>3. <i>Activase</i> (alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc.; December 2005.</p>\n<p>4. <i>Streptase</i> (streptokinase) [Australia summary of product characteristics]. Parkville, Australia: CSL Limited; February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3494":"<p><b>Title</b> Anticoagulants / Nonsteroidal Anti-Inflammatory Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK labeling lists the use of intravenous diclofenac in combination with anticoagulants (including low dose heparin) as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for signs and symptoms of bleeding if a nonsteroidal anti-inflammatory agent is combined with an anticoagulant.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Nonsteroidal anti-inflammatory agents (NSAIDs) and anticoagulants both increase the risk of bleeding. The concomitant use of NSAIDs and anticoagulants have an increased risk of serious<br>bleeding compared to the use of either drug alone.<sup>1,2,3</sup> If these agents are combined, monitor patients closely for signs and symptoms of bleeding.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; May 2016. </p>\n<p>2. Anaprox DS (naproxen) [prescribing information]. Alpharetta, GA: Canton Laboratories LLC; March 2017.</p>\n<p>3. Toradol (ketorolac) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; March 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3495":"<p><b>Title</b> Anticoagulants / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for signs and symptoms of bleeding if a salicylate is combined with an anticoagulant.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> Salicylates and anticoagulants both increase the risk of bleeding. The concomitant use of salicylates and anticoagulants may increase the risk of serious<br>bleeding compared to the use of either drug alone.<sup>1,2</sup> If these agents are combined, monitor patients closely for signs and symptoms of bleeding.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Salsalate [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; April 2008.</p>\n<p>2. Disgren (triflusal) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199301193. Accessed September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3496":"<p><b>Title</b> Anticoagulants / Thrombolytic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Avoid alteplase treatment of acute ischemic stroke (AIS) within 3 hours of symptom onset in patients receiving oral anticoagulants and with INR above 1.7. Avoid alteplase treatment of AIS 3-4.5 hours after symptom onset in patients receiving any oral anticoagulant, and consider avoiding any use of alteplase for AIS in patients receiving dabigatran, rivaroxaban, or apixaban. See full drug monograph for details.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for signs and symptoms of bleeding if thrombolytic agents are to be used with other drugs that alter coagulation, inhibit platelet function, or are thrombolytic. Use of such combinations may further increase the potential for bleeding complications. See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> As thrombolytics are agents that interfere with normal clotting function, the use of thrombolytics with other agents that interfere with coagulation may further increase the risk for bleeding complications.<sup>1,2,3</sup> As a result of the potential for an increased risk of bleeding with such combinations, careful monitoring for bleeding complications should accompany the use of any such combinations. This risk may persist for several days after discontinuation of the thrombolytic agent (but while the heparin, or similar agent, is continued).<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Retavase (reteplase). Fremont, CA: PDL BioPharma, Inc., November 2006.</p>\n<p>2. Prescribing information. TNKase (tenecteplase). South San Francisco, CA: Genentech, Inc., January 2008.</p>\n<p>3. Prescribing information. Activase (alteplase). South San Francisco, CA: Genentech, Inc., December 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3499":"<p><b>Title</b> Thrombolytic Agents / Salicylates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Salicylates should be discontinued, and enough time should elapse for their antiplatelet effects to subside, before initiation of long-term streptokinase treatment (new or continued aspirin use can still be considered).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for signs and symptoms of bleeding if thrombolytic agents are to be used with other drugs that alter coagulation, inhibit platelet function, or are thrombolytic. Use of such combinations may further increase the potential for bleeding complications. Antiplatelet agents should be discontinued, and enough time should elapse for their effects to subside, before initiation of long-term streptokinase treatment (new or continued aspirin use can still be considered).</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> As thrombolytics are agents that interfere with normal clotting function, the use of thrombolytics with other agents that interfere with coagulation (e.g., antiplatelet agents) may further increase the risk for bleeding complications.<sup>1,2,3,4</sup> As a result of the potential for an increased risk of bleeding, careful monitoring for bleeding complications should accompany the use of any such combinations. This risk may persist for several days after discontinuation of the thrombolytic agent (but while the heparin, or similar agent, is continued).<sup>1,2,3</sup> The streptokinase Australian summary of product characteristics specifically recommends that antiplatelet agents should be discontinued, and enough time should elapse for their effects to subside, before initiation of long-term streptokinase treatment.<sup>4</sup> One exception is the use of aspirin, whose use in combination with streptokinase may be beneficial under some circumstances.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Retavase</i> (reteplase) [prescribing information]. Fremont, CA: PDL BioPharma, Inc.; November 2006.</p>\n<p>2. <i>TNKase</i> (tenecteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc.; January 2008.</p>\n<p>3. <i>Activase</i> (alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc.; December 2005.</p>\n<p>4. <i>Streptase</i> (streptokinase) [Australia summary of product characteristics]. Parkville, Australia: CSL Limited; February 2011.</p>\n<p>5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. <i>Lancet</i>. 1988;2(8607):349-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2899772\">[PubMed 2899772]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}